NO155197B - ANALOGUE PROCEDURES FOR THE PREPARATION OF THERAPEUTIC ACTIVE ALPHACARBAMOYL-PYRROLPROPIONITRILS. - Google Patents

ANALOGUE PROCEDURES FOR THE PREPARATION OF THERAPEUTIC ACTIVE ALPHACARBAMOYL-PYRROLPROPIONITRILS. Download PDF

Info

Publication number
NO155197B
NO155197B NO801733A NO801733A NO155197B NO 155197 B NO155197 B NO 155197B NO 801733 A NO801733 A NO 801733A NO 801733 A NO801733 A NO 801733A NO 155197 B NO155197 B NO 155197B
Authority
NO
Norway
Prior art keywords
oxo
solution
methyl
substituted
formula
Prior art date
Application number
NO801733A
Other languages
Norwegian (no)
Other versions
NO801733L (en
NO155197C (en
Inventor
Gordon Northrop Walker
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO801733L publication Critical patent/NO801733L/en
Publication of NO155197B publication Critical patent/NO155197B/en
Publication of NO155197C publication Critical patent/NO155197C/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • C07D207/4162,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Antiinflammatory and antiarthritic compounds of the formula I <IMAGE> in which Pl denotes a 2- or 3-pyrrolyl radical, which is substituted in the 1-position by lower alkyl or Ph-lower alkyl and is unsubstituted in the three remaining positions or substituted by lower alkyl and/or a carboxyl or carboxy-lower alkoxy group; R represents lower alkyl and Ph denotes phenyl which is unsubstituted or substituted by one to three identical or different substituents from the group comprising lower alkyl, lower alkoxy, lower alkylthio, hydroxyl, halogen, trifluoromethyl, nitro, amino or lower alkanoylamino; these compounds in their enol form, their enol lower alkyl ethers or enol lower alkanoyl esters, or their salts with bases can be obtained, for example, by condensation of compounds of the formulae <IMAGE> in which X denotes lower alkoxy, lower alkanoyloxy or halogen.

Description

På spesiell måte substituerte "cyaneddiksyreani-lider" og beslektede "isoksazolyl-karboksylsyreanilider", Particularly substituted "cyanoacetic anilides" and related "isoxazolyl carboxylic anilides",

f.eks. slike med formlene: e.g. such with the formulas:

er i henhold til de belgiske patenter 842.688; 842.689; is according to the Belgian patents 842,688; 842,689;

849.343; 861.500 eller US-patent 4.061.767 "ikke-ulcerogene antiphlogistiske og analgetiske midler. 849,343; 861,500 or US Patent 4,061,767 “non-ulcerogenic antiphlogistic and analgesic agents.

Det er overraskende funnet at de nevnte nye pyrrolpropionitriler i forhold til de nevnte kjente anilider, It has surprisingly been found that the aforementioned new pyrrolepropionitrile in relation to the aforementioned known anilides,

men også i forhold til de meget gamle analoge benzoyl-for- but also in relation to the very old analogue benzoyl-for-

bindelser (J. Am.Chem. Soc. _3_5, 959, 1 91 3) f.eks. med hensyn til aktivitetsspektrum og holdbarhet byr på utpregede terapeutiske fordeler. bonds (J. Am.Chem. Soc. _3_5, 959, 1 91 3) e.g. in terms of spectrum of activity and durability offers distinct therapeutic advantages.

Foreliggende oppfinnelse vedrører analogifrem- The present invention relates to analogue

gangsmåter til fremstilling av nye terapeutisk aktive, methods for the production of new therapeutically active,

substituerte 0-okso-a-fenylkarbamoyl-pyrrolpropionitriler og deres enolderivater ned den generelle formel: substituted 0-oxo-α-phenylcarbamoyl-pyrrolepropionitriles and their enol derivatives down to the general formula:

hvori P1 betyr en 2- eller 3-pyrrolrest som i 1-stilling er substituert med Cj-C^-alkyl og i de gjenblivende tre still- in which P1 means a 2- or 3-pyrrole residue which is substituted in the 1-position with C1-C4-alkyl and in the remaining three positions

inger er usubstituert eller er substituert med en til tre inger is unsubstituted or is substituted by one to three

-C2~alkylgrupper og/eller en -C2-alkoksykarbonyl; og -C 2 -alkyl groups and/or a -C 2 -Alkoxycarbonyl; and

Ph står for fenyl, som er usubstituert eller substituert med en til to like eller forskjellige substituenter fra gruppen C^-C2-alkyl, C-^-C^-alkoksy, C^-C2-alkyltio, hydroksy, halogen, trifluormetyl, nitro, amino som er acetyl-aminosubsti-tuert, A betyr en oksogruppe eller betyr en -C^-C2-alkoksy-eller -O-CO-C-^-C-j-alkylgruppe, idet det da mellom de to naboplasserte karbonatomer består av dobbeltbinding, eller salter derav med baser eller terapeutisk anvendelige salter med baser. Ph stands for phenyl, which is unsubstituted or substituted with one to two identical or different substituents from the group C₁-C₂-alkyl, C₁-C₂-alkyl, C₁-C₂-alkylthio, hydroxy, halogen, trifluoromethyl, nitro , amino which is acetyl-amino substituted, A means an oxo group or means a -C₁-C₂-alkyl group , or salts thereof with bases or therapeutically useful salts with bases.

Begge av de nevnte pyrrolyl- og fenylgrupper Pl og Ph er fortrinnsvis C-usubstituert. De kan imidlertid også være substituert med en eller to like eller forskjellige substituenter fra gruppen laverealkyl, f.eks. metyl eller etyl. Dessuten kan resten Ph også være substituert med laverealkoksy, f.eks. metoksy, etoksy, n- eller i-prop-oksy eller -butoksy, laverealkyltio, f.eks. metyltio eller etyltio; hydroksy; halogen f.eks. fluor, klor eller brom; trifluormetyl; nitro; amino eller laverealkanoylamino, f.eks. acetylamino eller propionylamino. Resten Pl kan også inneholde en karbometoksy eller karbetoksy, spesielt i 3- eller 4-stilling. Both of the aforementioned pyrrolyl and phenyl groups P1 and Ph are preferably C-unsubstituted. However, they can also be substituted with one or two identical or different substituents from the lower alkyl group, e.g. methyl or ethyl. In addition, the residue Ph can also be substituted with lower alkoxy, e.g. methoxy, ethoxy, n- or i-propoxy or -butoxy, lower alkylthio, e.g. methylthio or ethylthio; hydroxy; halogen e.g. fluorine, chlorine or bromine; trifluoromethyl; nitro; amino or lower alkanoylamino, e.g. acetylamino or propionylamino. The residue P1 may also contain a carbomethoxy or carbethoxy, especially in the 3- or 4-position.

I pyrrolringens 1-stilling er laverealkyl-eller Ph-laverealkylgruppene fortrinnsvis metyl, men også etyl, n- eller i-propyl eller -butyl. In the 1-position of the pyrrole ring, the lower alkyl or Ph lower alkyl groups are preferably methyl, but also ethyl, n- or i-propyl or -butyl.

Uttrykket "lavere" definerer i det ovennevnte og i det følgende organiske rester eller forbindelser med maksimalt 7, fortrinnsvis 4, spesielt 1 eller 2 karbonatomer. The term "lower" defines in the above and in the following organic residues or compounds with a maximum of 7, preferably 4, especially 1 or 2 carbon atoms.

De B-hydroksy tautomere forbindelser med formel I er tilstrekkelig sure til å danne de nevnte C^-C^-alkyletere, enol-C^-C^-alkanoylestere, eller salter med baser, spesielt terapeutisk anvendbare salter med baser. Disse salter avledes fra et alkalimetall, jordalkalimetall, kobber- eller sinkhydroksyd, ammoniakk, av mono-, di- The B-hydroxy tautomeric compounds of formula I are sufficiently acidic to form the aforementioned C₁-C₂ alkyl ethers, enol C₁-C₂ alkanoyl esters, or salts with bases, especially therapeutically useful salts with bases. These salts are derived from an alkali metal, alkaline earth metal, copper or zinc hydroxide, ammonia, of mono-, di-

eller tri-(laverealkyl eller hydroksy-laverealkyl)-aminer, laverealkylenaminer eller laverealkylendiaminer. Slike salter er f.eks. natrium, kalium-, magnesium-, ammonium-, mono-, di- eller tri-(metyl, etyl eller hydroksyetyl)-ammonium-, pyrrolidinium-, etylendiammonium- eller morfolinium-salter eller deres forskjellige hydrater. or tri-(lower alkyl or hydroxy-lower alkyl) amines, lower alkylene amines or lower alkylene diamines. Such salts are e.g. sodium, potassium, magnesium, ammonium, mono-, di- or tri-(methyl, ethyl or hydroxyethyl) ammonium, pyrrolidinium, ethylenediammonium or morpholinium salts or their various hydrates.

Forbindelser av formel I viser verdifulle farmakologiske egenskaper, i første rekke anti-inflammatoriske og anti-artritt-virkninger. Disse kan påvirkes i in-vitro eller in-vivo forsøk. I sistnevnte anvendes fortrinnsvis pattedyr, f.eks. rotter, katter, marsvin eller hunder som prøveobjekter. Forbindelsen av formel I kan administreres enteralt, fortrinnsvis oralt, parenteralt, f.eks. subkutant eller intravenøst, eller topisk, f.eks. i form av oppløs-ninger i vann eller olje, eller i form av stivelsesholdige suspensjoner. Den anvendte dose kan ligge i et område mellom 0,1 og 100 mg/kg/dag, fortrinnsvis 1 til 50 mg/kg/dag, i første rekke 2 til 25 mg/kg/dag. De for de nevnte virkninger valgte prøver er enten klassiske forsøksmetoder f.eks. Carrageenin-podeødem- eller Adjuvans-artrittprøven på rotte, Synoviitis-forsøk på hund eller prøven hvori det ved ultrafiolett lys frembrakte erytem vurderes, eller moderne prøvemetoder. Slike er den nøytrale protease-hemming (beskrevet i Arthritis Rheum. YT_, 47, 1 974) eller hemmingen av leukozytne kjemotaksis (N.Y. Acad. Sei., 256, 177, 1975). Ytterligere metoder er avtak av neutrofiladher-ens (Amer. J. Med. 587, 1976) eller hemming av prostag-landin-syntease, hvilken prøve er omtalt i Biochem. 1j0, 2372, 1 971 . Compounds of formula I show valuable pharmacological properties, primarily anti-inflammatory and anti-arthritic effects. These can be affected in in-vitro or in-vivo experiments. In the latter, mammals are preferably used, e.g. rats, cats, guinea pigs or dogs as test subjects. The compound of formula I can be administered enterally, preferably orally, parenterally, e.g. subcutaneously or intravenously, or topically, e.g. in the form of solutions in water or oil, or in the form of starch-containing suspensions. The dose used can be in a range between 0.1 and 100 mg/kg/day, preferably 1 to 50 mg/kg/day, primarily 2 to 25 mg/kg/day. The samples chosen for the aforementioned effects are either classic test methods, e.g. The carrageenin graft edema or Adjuvant arthritis test in the rat, the Synoviitis test in the dog or the test in which the erythema produced by ultraviolet light is assessed, or modern test methods. Such are the neutral protease inhibition (described in Arthritis Rheum. YT_, 47, 1974) or the inhibition of leukocyte chemotaxis (N.Y. Acad. Sci., 256, 177, 1975). Additional methods are depletion of neutrophil adhesion (Amer. J. Med. 587, 1976) or inhibition of prostaglandin synthase, which test is discussed in Biochem. 1j0, 2372, 1 971 .

Illustrativ er følgende prøvemetode som gir en sakstjenende angivelse: Hann Charles River-rotter av en vekt på 250-300 g immuniseres med intradermale injeksjoner av 0,1 ml Bacillus Calmette Guerin-vaksine (BCG). Etter en uke administreres på forsøksdyrene for utløsning av anrik-ning av makrofager en injeksjon av 10 ml steril 2%-ig ris-stivelsesoppløsning intraperitonealt. På ellevte dag etter immuniseringen avlives dyrene og peritoneale makrofager samles med 20 ml Gey'scher pufret saltoppløsning som inneholder heparin (25 enheter pr. ml). Cellene sentrifugeres 10 min. ved 1 000 omdr./min., vaskes ytterligere i 50 ml Gey'scher oppløsning med samme hastighet og tid og suspen-deres deretter i Gey'scher oppløsning som inneholder 0,1% Ivumant-serumalbumin (Fraksjon V, Sigma Co,, pH = 7,1), for Illustrative is the following test method which provides a useful indication: Male Charles River rats weighing 250-300 g are immunized with intradermal injections of 0.1 ml of Bacillus Calmette Guerin (BCG) vaccine. After one week, an injection of 10 ml of sterile 2% rice starch solution is administered intraperitoneally to the test animals to trigger enrichment of macrophages. On the eleventh day after immunization, the animals are sacrificed and peritoneal macrophages are collected with 20 ml of Gey'scher buffered saline solution containing heparin (25 units per ml). The cells are centrifuged for 10 min. at 1,000 rpm, washed further in 50 ml of Gey'scher's solution at the same speed and time and then suspended in Gey'scher's solution containing 0.1% Ivumant serum albumin (Fraction V, Sigma Co, pH = 7.1), for

å oppnå en konsentrasjon på 2 x 10 celler pr. ml. to achieve a concentration of 2 x 10 cells per ml.

Med prøvestoffene fremstilles 1x10 mol opp-løsninger i dimetylacetamid. Følgende fortynnelser gjøres med Gey<1>scher oppløsning og disse has endelig til ovennevnte cellesuspensjon for å oppnå egnede sluttkonsentrasjoner på 10-4, 10-5, 10 og 10 mol. Etter innføring av suspen-sjonene i øvre del av modifiserte Boyden-kjemotaksis-kammere, forblir de nevnte prøvestoffene sammen med cellene. With the test substances, 1x10 mol solutions in dimethylacetamide are prepared. The following dilutions are made with Gey<1>scher's solution and these are finally added to the above-mentioned cell suspension to achieve suitable final concentrations of 10-4, 10-5, 10 and 10 mol. After introducing the suspensions into the upper part of modified Boyden chemotaxis chambers, the mentioned test substances remain together with the cells.

Som kjemotaktisk middel anvendes et rotteserum som er aktivert med lipopolysakkarid av Escherichia coli (Difco), (1/10 fortynning ved pH = 7,1). Dette serum ifylles i den nedre del av nevnte kamre. Den del av kamrene som inneholder cellene er adskilt fra den kjemotaktiske oppløsning ved hjelp av en cellulose-filtermembran som har porer av 8 mikron. Kamrene oppstilles i tre gangers gjentagelse og inkuberes 5 timer ved 37°C. Som kontroller på cellevandring anvendes cellesuspensjoner som ikke inneholder prøveforbindelser. Etter inkubasjonen fjernes filteret, fikseres og farges med jernhematoksylin ifølge Weigert. Fire felt av den nedre overflate av filteret undersøkes mikroskopisk med en 320 ganger forstørrelse. A rat serum activated with lipopolysaccharide of Escherichia coli (Difco) is used as a chemotactic agent (1/10 dilution at pH = 7.1). This serum is filled in the lower part of the aforementioned chambers. The part of the chambers containing the cells is separated from the chemotactic solution by means of a cellulose filter membrane which has pores of 8 microns. The chambers are set up in three repetitions and incubated for 5 hours at 37°C. Cell suspensions that do not contain test compounds are used as controls for cell migration. After the incubation, the filter is removed, fixed and stained with iron hematoxylin according to Weigert. Four fields of the lower surface of the filter are examined microscopically with a 320 times magnification.

Som indeks for den kjemotaktiske aktivitet anvendes gjen-nomsnittantallet av de i hvert av de fire felt talte neutrofiler. I denne prøvefremgangsmåte anvendes også indometacin og lavamisol som referanseforbindelser. The average number of neutrophils counted in each of the four fields is used as an index for the chemotactic activity. In this test procedure, indomethacin and lavamisole are also used as reference compounds.

Således er i adjuvansartritt-prøven f.eks. 1-metyl-p-okso-a-fenylkarbamoyl-2-pyrrolpropionitril en typisk representant for forbindelsen av formel I eller de nevnte enoletere eller enolester, salter eller deres anvendte forbindelser med formel I og II høyt aktive i rotter ved perorale doser ned til 2 mg/kg/dag. Innvirkningen av disse forbindelser på den in-vitro kjemotaktiske aktivitet av BCG-immuniserte makrofager er tydelig ved konsentrasjoner Thus, in the adjuvant arthritis test, e.g. 1-methyl-p-oxo-a-phenylcarbamoyl-2-pyrrolepropionitrile a typical representative of the compound of formula I or the mentioned enol ethers or enol esters, salts or their used compounds of formula I and II highly active in rats at oral doses down to 2 mg/kg/day. The effect of these compounds on the in-vitro chemotactic activity of BCG-immunized macrophages is evident at concentrations

— 5 —6 — 5 — 6

ved ned til 10 og 10 mol, og den ytrer seg i økning av makrofagenes kjemotaktiske reaksjon. I forhold til dette påvirker indometacin ikke makrofag-kjemotaksen, mens leva-misolen, en kjent immunpotensiator, frembringer en øket -3 -5 vandring ved sluttkonsentrasjoner fra 10 til 10 mol. at down to 10 and 10 mol, and it manifests itself in an increase in the macrophages' chemotactic reaction. In relation to this, indomethacin does not affect macrophage chemotaxis, while leva-misol, a known immunopotentiator, produces an increased -3 -5 migration at final concentrations from 10 to 10 mol.

De ovennevnte prøvemetoder viser såvel til den gode virkning av forbindelsen av formel I som også til en annen virkningsmekanisme, hvilke utmerker disse forbindelser i forhold til andre ikke-steroidale anti-inflamma-torisk virksomme forbindelser. Den i den makrofag-kjemo-taksiske prøve viste aktivitet er riktignok lik den av levamisol som er blitt klassifisert som et sykdomspåvirkende antireumatisk legemiddel. Forbindelsene av formel I som såvel har aktiviteten av indometacin-typen som også den av levamisol-typen, er verdifulle anti-inflammatoriske-og anti-artritt-midler f.eks. til behandling eller kontroll av betente artritt- og/eller dematopatologtilstander. De nye forbindelser kan dessuten anvendes som mellomprodukter til fremstilling av andre verdifulle, spesielt av farmakologisk virksomme preparater. The above-mentioned test methods point both to the good effect of the compound of formula I and also to another mechanism of action, which distinguishes these compounds in relation to other non-steroidal anti-inflammatory active compounds. The activity shown in the macrophage chemotaxic test is indeed similar to that of levamisole, which has been classified as a disease-influencing antirheumatic drug. The compounds of formula I, which have both indomethacin-type and levamisole-type activity, are valuable anti-inflammatory and anti-arthritic agents, e.g. for the treatment or control of inflammatory arthritis and/or dematopathological conditions. The new compounds can also be used as intermediates for the production of other valuable, especially pharmacologically active preparations.

Spesielt å fremheve er forbindelser med den generelle formel II: Of particular note are compounds of the general formula II:

hvori R betyr laverealkyl, hvert av symbolene R2 og R^ betyr hydrogen eller laverealkyl, og hvert av symbolene R^ og R,, betyr hydrogen, laverealkyl, laverealkoksy, hydroksy, halogen eller trifluormetyl, eller deres salter med baser, spesielt deres terapeutisk anvendbare baser. wherein R is lower alkyl, each of the symbols R 2 and R 2 is hydrogen or lower alkyl, and each of the symbols R 2 and R 2 is hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen or trifluoromethyl, or their salts with bases, especially their therapeutically useful bases.

Foretrukket er videre forbindelser med formel II hvori R^ betyr alkyl med maksimalt 4 karbonatomer, hvert av symbolene R2 og R^ betyr hydrogen, og hvert av symbolene R^ og R^ betyr hydrogen, alkyl eller alkoksy, hver gang med maksimalt 4 karbonatomer, fluor, klor eller trifluormetyl, eller deres salter med en base, spesielt deres terapeutisk anvendbare salter med baser. Further compounds of formula II are preferred in which R^ means alkyl with a maximum of 4 carbon atoms, each of the symbols R2 and R^ means hydrogen, and each of the symbols R^ and R^ means hydrogen, alkyl or alkoxy, each time with a maximum of 4 carbon atoms, fluorine, chlorine or trifluoromethyl, or their salts with a base, especially their therapeutically useful salts with bases.

Spesielt foretrukket er forbindelser med den Particularly preferred are compounds with it

generelle formel II, hvori betyr metyl, hvert av symbolene R2 og R^ betyr hydrogen, og hvert av symbolene R^ og R^ betyr hydrogen, metyl, metoksy, fluor, klor eller trifluormetyl, eller deres natrium-, kalium-, kalsium-, trietyl-ammnoium- eller trihydroksyetylammoniumsalter, idet et av symbolene R4 og R<-, som er forskjellig fra hydrogen, fortrinnsvis står i parastilling. general formula II, wherein is methyl, each of the symbols R 2 and R 2 is hydrogen, and each of the symbols R 2 and R 3 is hydrogen, methyl, methoxy, fluorine, chlorine or trifluoromethyl, or their sodium, potassium, calcium , triethylammonium or trihydroxyethylammonium salts, wherein one of the symbols R4 and R<-, which is different from hydrogen, is preferably in the para position.

Forbindelsene fremstilt ifølge oppfinnelsen fåes i etter i og for seg kjente metoder, f.eks. ved at The compounds produced according to the invention are obtained by methods known per se, e.g. by that

a) forbindelser med formlene: a) compounds with the formulas:

adderes og hvis nødvendig, N-substitueres en dannet forbindelse ved omsetning av reaksjonsdyktig ester av R-OH eller is added and, if necessary, N-substituted a formed compound by reaction of reactive ester of R-OH or

b) forbindelser med formlene: b) compounds with the formulas:

hvori X betyr laverealkoksy, laverealkanoyloksy eller wherein X means lower alkoxy, lower alkanoyloxy or

halogen, kondenseres eller halogen, condenses or

c) forbindelser med formlene: c) compounds with the formulas:

hvori Y betyr laverealkoksykarbonyl, halogenkarbonyl eller wherein Y means lower alkoxycarbonyl, halocarbonyl or

cyan, kondenseres og de dannede iminer hydrolyseres eller cyan, is condensed and the formed imines are hydrolyzed or

d) forbindelser med formel: d) compounds of formula:

isomeriseres med en sterk base og, hvis ønskelig, omdannes en isomerized with a strong base and, if desired, converted a

dannet forbindelse med formel I i en annen forbindelse ifølge oppfinnelsen og/eller hvis ønskelig, overføres et dannet enol i en enol-laverealkyleter eller enol-laverealkanoylester og/eller hvis ønskelig, øverføres et dannet enol i et salt med en base eller et dannet enolsalt i den fri enol eller i et annet salt med en base, og/eller hvis ønskelig, oppdeles en dannet blandning av isomerer i det enkelte isomer. formed compound of formula I in another compound according to the invention and/or if desired, a formed enol is transferred into an enol-lower alkyl ether or enol-lower alkanoyl ester and/or if desired, a formed enol is transferred into a salt with a base or a formed enol salt in the free enol or in another salt with a base, and/or if desired, a formed mixture of isomers is separated into the individual isomer.

Addisjonen av isocyanatet i fremgangsmåte a) gjennomføres fortrinnsvis ifølge de nevnte belgiske patenter eller ifølge US-patent nr. 3.905.997, dvs. i fravær eller i nærvær av en uorganisk eller organisk base, f.eks. natriumhydrid, eller i nærvær eller i fravær av et polart oppløs-ningsmiddel, f.eks. en eter som dietyleter eller tetrahydrofuran, og/eller et amid eller sulfoksyd, f.eks. dimetylformamid eller dimetylsulfoksyd, fortrinnsvis ved for-høyede temperaturer f.eks. ved omtrent 150°C, når ingen base anvendes. Den reaksjonsdyktige ester av alkoholen R-OH er avledet fra en sterk uorganisk syre eller en organisk sulfonsyre, f.eks. en halogenhydrogensyre eller p-toluolsulfonsyre. The addition of the isocyanate in method a) is preferably carried out according to the aforementioned Belgian patents or according to US patent no. 3,905,997, i.e. in the absence or in the presence of an inorganic or organic base, e.g. sodium hydride, or in the presence or absence of a polar solvent, e.g. an ether such as diethyl ether or tetrahydrofuran, and/or an amide or sulfoxide, e.g. dimethylformamide or dimethylsulfoxide, preferably at elevated temperatures, e.g. at about 150°C, when no base is used. The reactive ester of the alcohol R-OH is derived from a strong inorganic acid or an organic sulphonic acid, e.g. a hydrohalic acid or p-toluenesulfonic acid.

Fremgangsmåten ifølge oppfinnelsen gjennomføres fortrinnsvis som følger: Suspensjonen av det nevnte nitril i et aromatisk hydrokarbon, f.eks. i varm toluen behandles med et lite molart overskudd av vannfritt trilaverealkyl-amin, fortrinnsvis trietylamin. Deretter settes dertil en molekvivalent av fenylisocyanater Ph-N=C0 eller dets opp-løsning i et på forhånd nevnt polart oppløsningsmiddel, f.eks. dimetylsulfoksyd. Reaksjonsblandingen omrøres omtrent 2-12 timer ved værelsestemperatur og dets volum for-minskes under oppvarming ved ikke for høye temperaturer, f.eks. inntil 100°C. Den dannede utfelling opptas i en alkanol f.eks. metanol, og oppløsningen behandles med overskytende fortynnet vandig syre, f.eks. med 0,3 normal saltsyre. Det dannede råprodukt adskilles, vaskes med vann, tørkes, tritureres og/eller omkrystalliseres fra et egnet oppløsningsmiddel. Slike oppløsningsmidler er laverealkanoler, laverealkanoner, di-laverealkyleter og/ eller laverealkyl-laverelakanoater, f.eks. metanol, aceton, dietyleter og/eller eddiksyreetylester. The method according to the invention is preferably carried out as follows: The suspension of the aforementioned nitrile in an aromatic hydrocarbon, e.g. in hot toluene is treated with a small molar excess of anhydrous trilower alkylamine, preferably triethylamine. A molar equivalent of phenyl isocyanates Ph-N=C0 or its solution in a previously mentioned polar solvent, e.g. dimethyl sulfoxide. The reaction mixture is stirred for approximately 2-12 hours at room temperature and its volume is reduced during heating at not too high temperatures, e.g. up to 100°C. The formed precipitate is taken up in an alkanol, e.g. methanol, and the solution treated with excess dilute aqueous acid, e.g. with 0.3 normal hydrochloric acid. The crude product formed is separated, washed with water, dried, triturated and/or recrystallized from a suitable solvent. Such solvents are lower alkanols, lower alkanones, di-lower alkyl ethers and/or lower alkyl-lower alkanoates, e.g. methanol, acetone, diethyl ether and/or acetic acid ethyl ester.

Amineringen etter fremgangsmåte b) gjennomføres også på vanlig måte, fortrinnsvis mellom værelsestemperatur og omtrent 150°C. Man arbeider enten med ekvivalente mengder av reaksjonspartnerne, fortrinnsvis når det anvendes en ester, eller med et aminoverskudd, eller i nærvær av en annen base. Slike baser er f.eks. tertiære aminer som et tri-laverealkyl-amin eller pyridin. Disse anvendes ved anvendelse av halo-genid- eller anhydridutgangsstoffer for nøytralisering av den dannede syre. Den i reaksjonen av esterutgangsstoffer dannede laverealkanol avdestilleres fortrinnsvis sammen med oppløsningsmidlet, f.eks. med aromatisk hydrokarbon, f.eks. benzen, toluen eller xylen. The amination according to method b) is also carried out in the usual way, preferably between room temperature and approximately 150°C. One works either with equivalent amounts of the reaction partners, preferably when an ester is used, or with an excess of amine, or in the presence of another base. Such bases are e.g. tertiary amines such as a tri-lower alkyl amine or pyridine. These are used when halogenide or anhydride starting materials are used to neutralize the acid formed. The lower alkanol formed in the reaction of ester starting materials is preferably distilled off together with the solvent, e.g. with aromatic hydrocarbon, e.g. benzene, toluene or xylene.

Kondensasjon i fremgangsmåte c) foretas fortrinnsvis under anvendelse av alkalimetaller, deres lavere alkoksy-der eller spesielt hydrider, f.eks. natriumhydrid i de nevnte polare oppløsningsmidler, fortrinnsvis dimetylformamid eller dimetylsulfoksyd. Denne kondensasjon er analog til fremstillingen av de nevnte nitrile utgangsstoffer for fremgangsmåter a) og b), hvis kondensasjon er vist i de tilsvarende eksempler. Condensation in method c) is preferably carried out using alkali metals, their lower alkoxides or especially hydrides, e.g. sodium hydride in the aforementioned polar solvents, preferably dimethylformamide or dimethylsulfoxide. This condensation is analogous to the preparation of the aforementioned nitrile starting materials for methods a) and b), whose condensation is shown in the corresponding examples.

Endelig gjennomføres isomeriseringen i fremgangsmåte d) i nærvær av sterke uorganiske eller organiske baser, f.eks. ammoniumhydroksyder, f.eks. trimetylbenzyl-ammonium-hydroksyd. Finally, the isomerization in method d) is carried out in the presence of strong inorganic or organic bases, e.g. ammonium hydroxides, e.g. trimethylbenzyl ammonium hydroxide.

De dannede forbindelser med formel I kan på i The formed compounds of formula I can on i

og for seg kjent måte overføres i hverandre. Således kan f.eks. dannede enoler foretres, fortrinnsvis med diazol-alkaner eller f.eks. med laverealkansyreanhydrider. Terapeutiske anvendbare salter av de nevnte enoler kan f.eks. fremstilles ved vandige alkalimetallhydroksyder, fortrinnsvis i nærvær av en eter eller alkohol som oppløsningsmiddel, f.eks. en laverealkanol. Fra de alkoholiske oppløsninger kan saltene utfelles med de nevnte etere, f.eks. dietyleter eller tetrahydrofuran. Man arbeider med måtelige tempera- and are transferred in a manner known to each other. Thus, e.g. formed enols are preferred, preferably with diazole alkanes or e.g. with lower alkanoic anhydrides. Therapeutically applicable salts of the mentioned enols can e.g. is prepared by aqueous alkali metal hydroxides, preferably in the presence of an ether or alcohol as solvent, e.g. a lower alkanol. From the alcoholic solutions, the salts can be precipitated with the aforementioned ethers, e.g. diethyl ether or tetrahydrofuran. One works with moderate tempera-

turer, f.eks. under 100°C. Dannede salter kan som nevnt ovenfor omdannes ved behandling med syrer i de frie forbindelsene. Også en nitrogruppe i resten Ph kan, f.eks. trips, e.g. below 100°C. Formed salts can, as mentioned above, be converted by treatment with acids in the free compounds. Also a nitro group in the residue Ph can, e.g.

med katalyttisk aktivert hydrogen, som hydrogen i nærvær av nikkel- eller palladiumkatalysatorer, overføres i aminogrup-pen. Sistnevnte kan enten acyleres som nevnt ovenfor eller med laverealkansyrehalogenider eller laverealkylestere. with catalytically activated hydrogen, such as hydrogen in the presence of nickel or palladium catalysts, is transferred in the amino group. The latter can either be acylated as mentioned above or with lower alkanoic acid halides or lower alkyl esters.

Utgangsstoffene er kjente, eller hvis de er nye, kan de fremstilles ifølge de for analoge forbindelser omtalte fremgangsmåter, f.eks. de som er omtalt i teknikken som for de der nevnte forbindelser, eller som vist i eksemplene. The starting materials are known, or if they are new, they can be prepared according to the methods mentioned for analogous compounds, e.g. those mentioned in the art as for the compounds mentioned there, or as shown in the examples.

Utgangsstoffer og sluttprodukter som er isomer-blandinger, kan oppdeles etter i og for seg kjente metoder, f.eks. ved fraksjonerte destilleringer, krystallisering og/ eller kromatografi i de enkelte isomerer. Starting materials and end products that are isomer mixtures can be separated according to methods known per se, e.g. by fractional distillations, crystallization and/or chromatography in the individual isomers.

De ovennevnte reaksjoner gjennomføres etter i og for seg kjente metoder i nærvær eller fravær av fortynnings-middel, fortrinnsvis slike som er inert overfor reagensene og oppløser disse, katalysatorer, kondensasjonsmidler eller nøytralisasjonsmidler og/eller i en inert atmosfære under avkjøling, ved værelsestemperatur eller ved forhøyede temperaturer, ved normalt eller forhøyet trykk. The above-mentioned reactions are carried out according to per se known methods in the presence or absence of diluents, preferably those which are inert towards the reagents and dissolve them, catalysts, condensation agents or neutralizing agents and/or in an inert atmosphere under cooling, at room temperature or at elevated temperatures, at normal or elevated pressure.

Ved fremgangsmåten ifølge oppfinnelsen anvendes fortrinnsvis slike utgangsstoffer som fører til de inn-ledningsvis som spesielt verdifulle omtalte forbindelser, spesielt slike med formel II. In the method according to the invention, such starting materials are preferably used which lead to the compounds mentioned at the outset as particularly valuable, especially those with formula II.

De farmakologiske anvendbare forbindelsene kan anvendes ved fremstilling av farmasøytiske preparater som inneholder en virksom mengde av det aktive stoff sammen eller i blanding med bærestoffer som egner seg entral- The pharmacologically applicable compounds can be used in the preparation of pharmaceutical preparations containing an effective amount of the active substance together or in admixture with carriers suitable for entral-

eller parenteral administrering. or parenteral administration.

Oppfinnelsen skal forklares ved hjelp av noen eksempler. Temperaturer angis i Celsius-grader, og angiv-elsen vedrørende deler er vektdeler. Når intet annet er angitt, gjennomføres inndamping av oppløsningsmidlet under atmosfærisk trykk.'The invention shall be explained by means of some examples. Temperatures are stated in degrees Celsius, and the indication regarding parts is parts by weight. When nothing else is specified, evaporation of the solvent is carried out under atmospheric pressure.'

Eksempel 1 Example 1

1- metyl- g- okso- g- fenylkarbamoyl- 2- pyrrolpropionitril 1- methyl- g- oxo- g- phenylcarbamoyl- 2- pyrrole propionitrile

En suspensjon av 12,9 g 1 -metyl-(i-okso-2-pyrrolpropionitril i 150 ml tørr toluen og 10,1 g vannfritt trietylamin blandes under omrøring med 10,7 g fenylisocyanat. Etter oppløsning av faste stoffer holdes den mørkerøde opp-løsning 30 min. ved værelsestemperatur, 5 min. på dampbad og natten over ved værelsestemperatur. Blandingen inndampes på dampbad, residuet opptas i metanol, og oppløsningen helles i blandingen av 25 ml 5-normal klorhydrogensyre og 600 ml vann. De dannede lysebrune krystaller adskilles, vaskes med vann, tritureres med etanol og omkrystalliseres fra omtrent 2200 A suspension of 12.9 g of 1-methyl-(i-oxo-2-pyrrolepropionitrile in 150 ml of dry toluene and 10.1 g of anhydrous triethylamine is mixed with stirring with 10.7 g of phenyl isocyanate. After dissolution of solids, the dark red solution for 30 min at room temperature, 5 min on a steam bath and overnight at room temperature. The mixture is evaporated on a steam bath, the residue is taken up in methanol, and the solution is poured into the mixture of 25 ml of 5-normal hydrochloric acid and 600 ml of water. The light brown crystals formed separated, washed with water, triturated with ethanol and recrystallized from about 2200

ml metanol. Man får 1-metyl-Ø-okso-a-fenylkarbamoyl-2-pyrrolpropionitril med formel: ml of methanol. 1-Methyl-Ø-oxo-α-phenylcarbamoyl-2-pyrrolepropionitrile is obtained with the formula:

som smelter ved 174-175°C. which melts at 174-175°C.

Utgangsstoffet fremstilles som følger: En oppløs-ning av 28 g 1-metylpyrrol-2-karboksylsyre i 20 ml dimetylformamid tilsettes en suspensjon som er fremstilt idet man går ut fra 12 g 50%-ig natriumhydrid i mineralolje ved vasking med petroleter eller suspendering i 50 ml dimetylformamid under omrøring og avkjøling. Reaksjonsblandingen blandes deretter med 30 ml metyljodid og omrøres videre ved værelsestemperatur. Etter avslutning av den til å begynne med isotermiske reaksjon, setter man ytterligere til 10 ml metyljodid. Man lar reaksjonsblandingen stå natten over, behandler den med vann og ekstraherer den med dietyleter. Ekstraktet vaskes med vandig natriumkarbonat-oppløsning og vann, tørkes og inndampes. Man får den oljeaktige 1-metylpyrrol-2-karboksylsyremetylester. En oppløsning av 28 g av sistnevnte forbindelse i 50 ml acetonitril settes under omrøring til en suspensjon som er fremstilt av 19 g 50%-lg natriumhydrid i mineralolje, ved vasking med petroleter og suspendering i 50 ml dimetylformamid. Etter avslutning av den isotermiske reaksjon oppvarmes blandingen 15 min. på dampbad idet det finner sted en videre livlig sprudlende reaksjon. Den tyktflytende rødbrune suspensjon fortynnes med ytterligere 50 ml dimetylformamid og hensettes natten over ved værelsestemperatur. Blandingen oppvarmes, deretter igjen på dampbad i 5 min., avkjøles deretter og fortynnes'mefl tyann.-. Den vandige oppløsning filtreres, vaskes en gang med dietyleter og surgjøres med klorhydrogensyre. De dannede krystaller adskllles, vaskes med vann, tørkes, tritureres med kald etanol og omkrystalliseres fra etanol. Man får 1-metyl-3-okso-2-pyrrolpropionitril, som smelter The starting material is prepared as follows: A solution of 28 g of 1-methylpyrrole-2-carboxylic acid in 20 ml of dimethylformamide is added to a suspension that is prepared starting from 12 g of 50% sodium hydride in mineral oil by washing with petroleum ether or suspending in 50 ml of dimethylformamide while stirring and cooling. The reaction mixture is then mixed with 30 ml of methyl iodide and stirred further at room temperature. After completion of the initially isothermal reaction, a further 10 ml of methyl iodide is added. The reaction mixture is allowed to stand overnight, treated with water and extracted with diethyl ether. The extract is washed with aqueous sodium carbonate solution and water, dried and evaporated. The oily 1-methylpyrrole-2-carboxylic acid methyl ester is obtained. A solution of 28 g of the latter compound in 50 ml of acetonitrile is stirred into a suspension prepared from 19 g of 50%-lg sodium hydride in mineral oil, by washing with petroleum ether and suspending in 50 ml of dimethylformamide. After completion of the isothermal reaction, the mixture is heated for 15 min. on a steam bath as a further lively bubbling reaction takes place. The viscous red-brown suspension is diluted with a further 50 ml of dimethylformamide and allowed to stand overnight at room temperature. The mixture is heated, then again on a steam bath for 5 min., then cooled and diluted'mefl tyann.-. The aqueous solution is filtered, washed once with diethyl ether and acidified with hydrochloric acid. The formed crystals are separated, washed with water, dried, triturated with cold ethanol and recrystallized from ethanol. 1-Methyl-3-oxo-2-pyrrolepropionitrile is obtained, which melts

ved 107-109°C. at 107-109°C.

Eksempel 2 Example 2

1- metyl- 3- okso- q- fenylkarbamoyl- 2- pyrrolpropionitril, Na- salt, K- salt og Ca- salt 1- methyl- 3- oxo- q- phenylcarbamoyl- 2- pyrrole propionitrile, Na- salt, K- salt and Ca- salt

Ved behandling av ekvivalente mengder konsentrert vandig oppløsning av natriumhydroksyd, kaliumhydroksyd, eller kalsiumhydroksyd med 1-metyl-ø-okso-a-fenylkarbamoyl-2- pyrrolproplonitril, filtrering av blandingen og inndamping av filtratet til tørrhet» får man de tre tilsvarende metall-salter. Disse synes ikke å ha godt definerte krystallinske egenskaper eller smeltepunkter, selvom de igjen kan utfelles fra etanoliske oppløsninger ved tilsetning av dietyleter. Saltene er vannoppløselige og de viser i infrarød-spektrum følgende bånd: By treating equivalent amounts of concentrated aqueous solution of sodium hydroxide, potassium hydroxide, or calcium hydroxide with 1-methyl-o-oxo-a-phenylcarbamoyl-2-pyrroleproplonitrile, filtering the mixture and evaporating the filtrate to dryness', the three corresponding metal salts are obtained . These do not seem to have well-defined crystalline properties or melting points, although they can again be precipitated from ethanolic solutions by the addition of diethyl ether. The salts are water-soluble and they show the following bands in the infrared spectrum:

Na-salt: 4,57; 6,17 og 6,29 y Na salt: 4.57; 6.17 and 6.29 y

K-salt: 4,58; 6,17 og 6,30 y K salt: 4.58; 6.17 and 6.30 y

Ca-salt: 4,55; 6,13 og 6,23 y Ca salt: 4.55; 6.13 and 6.23 y

I hvert tilfelle tilbakevinnes ved surgjøring av den vandige saltoppløsning med klorhydrogensyre den iden-tiske frie forbindelse (smeltepunkt 174-175°C). In each case, the identical free compound (melting point 174-175°C) is recovered by acidifying the aqueous salt solution with hydrochloric acid.

Eksempel 3 Example 3

1- metyl- P- okso- g- fenylkarbamoyl- 2- pyrrolpropionitril-trishydroksyetylammoniumsalt 1- methyl- P- oxo- g- phenylcarbamoyl- 2- pyrrolepropionitrile-trishydroxyethylammonium salt

En suspensjon av 21,4 g 1-metyl-p-okso-g<->fenylkarbamoyl-2-pyrrolpropionitril i 100 ml absolutt etanol blandes med 11,68 ml trisetanolamin i 25 ml etanol og oppvarmes til avslutning av oppløsningen. Oppløsningen filtreres varm, avkjøles under omrøring til værelsestemperatur, den dannede suspensjon avkjøles til 10°C, filtreres og residuet vaskes med 25 ml kald etanol. Man får det tilsvarende tris-hydroksyetylammoniumsalt som smelter ved 115-117°C. A suspension of 21.4 g of 1-methyl-p-oxo-g<->phenylcarbamoyl-2-pyrrolepropionitrile in 100 ml of absolute ethanol is mixed with 11.68 ml of triethanolamine in 25 ml of ethanol and heated to complete dissolution. The solution is filtered hot, cooled with stirring to room temperature, the suspension formed is cooled to 10°C, filtered and the residue is washed with 25 ml of cold ethanol. The corresponding tris-hydroxyethylammonium salt is obtained which melts at 115-117°C.

Eksempel 4 Example 4

1- metyl-&- metoksy- a- fenylkarbamoyl- 2- pyrrolakrylnitril 1- methyl-&- methoxy- a- phenylcarbamoyl- 2- pyrrolacrylonitrile

Man setter 3,8 g 1 -metyl-(3-okso-g-fenylkarbamoyl-2- pyrrolpropionitril til 500 ml eterisk diazometan som fremstilles av 10,3 g N-nitroso-N-metylurinstoff med 35 ml 45%-ig vandig kaliumhydroksydoppløsning, og tørkes over slike tabletter. Etter avslutning av nitrogenutviklingen filtreres oppløsningen og inndampes. Residuet tritureres med dietyleter og omkrystalliseres fra eddiksyreetylester. Man får den tilsvarende metylenoleter, nemlig 1-metyl-3-metoksy-g<->fenylkarbamoyl-2-pyrrolakrynitril som smelter ved 121-122°C. Eksempel 5 3.8 g of 1-methyl-(3-oxo-g-phenylcarbamoyl-2-pyrrolepropionitrile) are added to 500 ml of ethereal diazomethane, which is prepared from 10.3 g of N-nitroso-N-methylurea with 35 ml of a 45% aqueous potassium hydroxide solution . melts at 121-122° C. Example 5

1- metyl- ft- okso- g-( p- fluorfenylkarbamoyl)- 2- pyrrolpropionitril 1- methyl- ft- oxo- g-( p- fluorophenylcarbamoyl)- 2- pyrrolepropionitrile

En suspensjon av 4 g 1-metyl-3-okso-2-pyrrolpropionitril i 70 ml tolun og 3,2 g trietylamin blandes under om-røring med 3,7 g p-fluorfenylisocyanat. Blandingen oppvarmes på dampbad til oppløsningen av det faste materiale og den rødbrune oppløsning hensettes natten over ved værelsestemperatur. Reaksjonsblandingen inndampes på dampbad, residuet opptas i metanol og oppløsningen helles i en blanding av 8 ml 5-normal klorhydrogensyre og 300 ml vann. De utfelte krystaller adskilles, vaskes med vann, tørkes, tritureres med metanol og omkrystalliseres fra eddiksyreetylester. Man får 1 -metyl-(3-okso-a- (p-f luorf enylkarbamoyl) -2-pyrrolpropionitril som smelter ved 198-199°C. A suspension of 4 g of 1-methyl-3-oxo-2-pyrrolepropionitrile in 70 ml of toluene and 3.2 g of triethylamine is mixed with stirring with 3.7 g of p-fluorophenyl isocyanate. The mixture is heated on a steam bath until the solid material dissolves and the reddish-brown solution is left overnight at room temperature. The reaction mixture is evaporated on a steam bath, the residue is taken up in methanol and the solution is poured into a mixture of 8 ml of 5-normal hydrochloric acid and 300 ml of water. The precipitated crystals are separated, washed with water, dried, triturated with methanol and recrystallized from ethyl acetate. 1-Methyl-(3-oxo-α-(p-fluorophenylcarbamoyl)-2-pyrrolepropionitrile is obtained which melts at 198-199°C.

Eksempel 6 Example 6

1- metyl- ft- okso- a- fenylkarbamoyl- 2- pyrrolpropionitril 1- methyl- ft- oxo- a- phenylcarbamoyl- 2- pyrrole propionitrile

En blanding av 1,1 g 1-metyl-Ø-okso-a-etoksykarbonyl-2-pyrrolpropionitril, 1,1 g anilin og 60 ml xylol kokes 4,5 time under tilbakeløp. Reaksjonsblandingen lar man av-kjøle natten over og hensettes ved værelsestemperatur. Deretter filtreres oppløsningen, inndampes og residuet omkrystalliseres fra metanol. Man får 1-metyl-p-okso-a-fenylkarbamoyl-2-pyrrolpropionitril som smelter ved 173-174°C. Produktet er identisk med produktet fra eksempel 1. A mixture of 1.1 g of 1-methyl-Ø-oxo-α-ethoxycarbonyl-2-pyrrolepropionitrile, 1.1 g of aniline and 60 ml of xylol is refluxed for 4.5 hours. The reaction mixture is allowed to cool overnight and allowed to stand at room temperature. The solution is then filtered, evaporated and the residue recrystallized from methanol. 1-Methyl-p-oxo-a-phenylcarbamoyl-2-pyrrolepropionitrile is obtained which melts at 173-174°C. The product is identical to the product from example 1.

Utgangsstoffet fremstilles som følger: En oppløs-ning av 10 g 1-metylpyrrol-2-karboksylsyre i 650 ml tørr dietyleter og 8,5 g vannfritt trietylamin blandes trinnvis under omrøring med en oppløsning av 6 ml tionylklorid i 50 ml dietyleter. Reaksjonsblandingen filtreres etter 30 min. <p>g residuet vaskes med dietyleter. Filtratet inndampes til et mindre volum, filtreres igjen og inndampes endelig under nedsatt trykk. Man får det tilsvarende syreklorid. The starting material is prepared as follows: A solution of 10 g of 1-methylpyrrole-2-carboxylic acid in 650 ml of dry diethyl ether and 8.5 g of anhydrous triethylamine is mixed in stages with stirring with a solution of 6 ml of thionyl chloride in 50 ml of diethyl ether. The reaction mixture is filtered after 30 min. The <p>g residue is washed with diethyl ether. The filtrate is evaporated to a smaller volume, filtered again and finally evaporated under reduced pressure. You get the corresponding acid chloride.

Dets oppløsning i 20 ml etylenglykoldimetyleter settes langsomt under omrøring og avkjøling til en suspensjon av 7,2 g 50%-ig natriumhydrid i mineralolje (vasket med petroleter) i 50 ml dimetylformamid og 20 g cyaneddiksyre-etylester. Den eksotermiske reaksjon aksellereres ved kort oppvarming av blandingen på dampbad. Reaksjonsblandingen hensettes natten over, behandles med vann, surgjøres med 5-normal klorhydrogensyre og ekstraheres med dietyleter. Ekstraktet blir vasket med vann, tørkes, inndampes og residuet tritureres og omkrystalliseres fra dietyleter. Man får 1-metyl-Ø-okso-a-etoksykarbonyl-2-pyrrolpropionitril som smelter ved 74-77°C. Its solution in 20 ml of ethylene glycol dimethyl ether is added slowly with stirring and cooling to a suspension of 7.2 g of 50% sodium hydride in mineral oil (washed with petroleum ether) in 50 ml of dimethylformamide and 20 g of cyanoacetic acid ethyl ester. The exothermic reaction is accelerated by briefly heating the mixture in a steam bath. The reaction mixture is allowed to stand overnight, treated with water, acidified with 5-normal hydrochloric acid and extracted with diethyl ether. The extract is washed with water, dried, evaporated and the residue triturated and recrystallized from diethyl ether. 1-Methyl-Ø-oxo-α-ethoxycarbonyl-2-pyrrolepropionitrile is obtained which melts at 74-77°C.

Det samme produkt fåes ved acylering med det blandede anhydrid, dvs. ved anvendelse av ekvivalent mengde av klormaursyreetylester i stedet for tionylklorid i ovennevnte reaksjonstrinn. The same product is obtained by acylation with the mixed anhydride, i.e. by using an equivalent amount of chloroformate ethyl ester instead of thionyl chloride in the above reaction step.

Eksempel 7 Example 7

1- metyl- ft- okso- g-( p- hydroksyfenylkarbamoyl)- 2- pyrrolpropionitril 1- methyl- ft- oxo- g-( p- hydroxyphenylcarbamoyl)- 2- pyrrolepropionitrile

En blanding av 5,7 g 1-metyl-3-okso-a-etoksykarbonyl-2-pyrrolpropionitril, 3,6 g p-aminofenol og 300 ml xylol kokes 2 timer under tilbakeløp og filtreres. Filtratet avkjøles, de dannede krystaller adskilles og omkrystalliseres fra metanol. Man får 1-metyl-3-okso-a-(p-hydroksy-fenylkarbamoyl)-2-pyrrolpropionitril som smelter ved 182-184°C. A mixture of 5.7 g of 1-methyl-3-oxo-α-ethoxycarbonyl-2-pyrrolepropionitrile, 3.6 g of p-aminophenol and 300 ml of xylol is refluxed for 2 hours and filtered. The filtrate is cooled, the crystals formed are separated and recrystallized from methanol. 1-Methyl-3-oxo-α-(p-hydroxy-phenylcarbamoyl)-2-pyrrolepropionitrile is obtained which melts at 182-184°C.

Eksempel 8 Example 8

1- metyl- 3- okso- g- fenylkarbamoyl- 2- pyrrolpropionitril 1- methyl- 3- oxo- g- phenylcarbamoyl- 2- pyrrole propionitrile

En oppløsning av 4 g fenylkarbamoylacetonitril i 5 0 ml dimetylformamid blandes under omrøring i en nitrogenatmosfære med 28 g kalium-tert.-butoksyd. Etter 2 timer av-kjøles den dannede suspensjon til 5°C og blandes i løpet av 10 min. med 4,1 g 1-metylpyrrol-2-karboksylsyreklorid A solution of 4 g of phenylcarbamoylacetonitrile in 50 ml of dimethylformamide is mixed with stirring in a nitrogen atmosphere with 28 g of potassium tert.-butoxide. After 2 hours, the formed suspension is cooled to 5°C and mixed during 10 min. with 4.1 g of 1-methylpyrrole-2-carboxylic acid chloride

(US-PS nr. 3.551.571). Reaksjonsblandingen omrøres i 18 timer ved værelsestemperatur, helles i 300 ml isvann, og den dannede utfelling frafiltreres. Denne vaskes med vann, tørkes og omkrystalliseres fra etanol. Man får 1-metyl-3-okso-a-fenylkarbamoyl-2-pyrrolpropionitril som smelter ved 172-174°C. Produktet er identisk med produktet fra eksempel 1 . (US-PS No. 3,551,571). The reaction mixture is stirred for 18 hours at room temperature, poured into 300 ml of ice water, and the formed precipitate is filtered off. This is washed with water, dried and recrystallized from ethanol. 1-Methyl-3-oxo-α-phenylcarbamoyl-2-pyrrolepropionitrile is obtained which melts at 172-174°C. The product is identical to the product from example 1.

Utgangsstoffet fremstilles som følger: En blanding av 42,53 g cyaneddiksyre, 46,56 g anilin og 500 ml acetonitril blandes i løpet av 3 0 min. under omrørino i en nitrogenatmosfære med en oppløsning av 113,7 g N,N-dicyklo-heksylkarbodiimid i 500 ml acetonitril. Etter 3 timer filtreres den dannede suspensjon, residuet vaskes med 200 ml acetonitril og filtratet inndampes. Residuet tritureres med 500 ml dietylester og 50 ml eddiksyreetylester, filtreres og tørkes. Man får fenylkarbamoylacetonitril som smelter ved 200-202°C. The starting material is prepared as follows: A mixture of 42.53 g cyanoacetic acid, 46.56 g aniline and 500 ml acetonitrile is mixed during 30 min. under stirring in a nitrogen atmosphere with a solution of 113.7 g of N,N-dicyclohexylcarbodiimide in 500 ml of acetonitrile. After 3 hours, the resulting suspension is filtered, the residue is washed with 200 ml of acetonitrile and the filtrate is evaporated. The residue is triturated with 500 ml diethyl ester and 50 ml acetic acid ethyl ester, filtered and dried. Phenylcarbamoylacetonitrile is obtained which melts at 200-202°C.

Eksempel 9 Example 9

1- metyl- 3- okso- a- fenylkarbamoyl- 2- pyrrolpropionitril og trls-hydroksyetylammoniumsalt derav 1- methyl- 3- oxo- a- phenylcarbamoyl- 2- pyrrole propionitrile and trls-hydroxyethylammonium salt thereof

En suspensjon av '1,135 g 1-metyl-p-okso-2-pyrrolpropionitril i 17000 ml tørr toluen, blandes under omrøring i nitrogenatmosfære først med 913 g vannfritt trietylamin og deretter med 913 g fenylisocyanat. Den dannede mørkebrune oppløsning omrøres natten over ved værelsestemperatur og inndampes deretter ved 60-70°C/10 mm Hg. Residuet opptas i 1400 ml metanol og oppløsningen behandles med 1400 ml 6-normal klorhydrogensyre i 4200 ml vann. Suspensjonen av-kjøles 20 min. til 15-20°C, filtreres og residuet vaskes 2 ganger med 1800 ml vann, 2 ganger med 1000 ml isopropanol og 13 ganger med 1000 ml dietyleter. Det røde residuet tørkes ved 6 0°C og 5 mm Hg til vektkonstant. Man oppløser 1960 g av dette residuet i 44400 ml metylenklorid ved værelsestemperatur. Oppløsningen behandles med 400 g aktivt kull, filtreres og filtratet inndampes. Residuet tritureres med 12000 ml vannfri etanol, suspensjonen filtreres ved 20°C, vaskes 4 ganger med 1000 ml vannfri etanol og tørkes ved 60°C og 5 mm Hg. Man får 1-metyl-3-okso-g<->fenylkarbamoyl-2- pyrrolpropionitril som smelter ved 172-174°C. Produktet er identisk med produkter fra eks. 1, 6 eller 8. A suspension of 1.135 g of 1-methyl-p-oxo-2-pyrrolepropionitrile in 17,000 ml of dry toluene is mixed with stirring in a nitrogen atmosphere first with 913 g of anhydrous triethylamine and then with 913 g of phenyl isocyanate. The dark brown solution formed is stirred overnight at room temperature and then evaporated at 60-70°C/10 mm Hg. The residue is taken up in 1400 ml of methanol and the solution is treated with 1400 ml of 6-normal hydrochloric acid in 4200 ml of water. The suspension is cooled for 20 min. to 15-20°C, filtered and the residue washed 2 times with 1800 ml of water, 2 times with 1000 ml of isopropanol and 13 times with 1000 ml of diethyl ether. The red residue is dried at 60°C and 5 mm Hg to constant weight. 1960 g of this residue is dissolved in 44400 ml of methylene chloride at room temperature. The solution is treated with 400 g of activated charcoal, filtered and the filtrate evaporated. The residue is triturated with 12,000 ml of anhydrous ethanol, the suspension is filtered at 20°C, washed 4 times with 1,000 ml of anhydrous ethanol and dried at 60°C and 5 mm Hg. 1-Methyl-3-oxo-g<->phenylcarbamoyl-2-pyrrolepropionitrile is obtained which melts at 172-174°C. The product is identical to products from e.g. 1, 6 or 8.

Man suspenderer 1801 g av sistnevnte forbindelse 1801 g of the latter compound are suspended

i 10500 ml vannfri etanol og tilsetter 1108 g trietanolamin. Blandingen omrøres til oppløsning av det faste materialet og oppvarmes deretter og avkjøles langsomt til 20°C. Den dannede utfelling frafUtreres, vaskes 2 ganger med 1000 ml kald, vannfri etanol og tørkes ved 4 5°C og 0,1 mm Hg. Man får det tilsvarende tris-hydroksyetylammoniumsalt som smelter ved 115-117°C. Saltet er identisk med saltet fra eks. 3. in 10,500 ml of anhydrous ethanol and adds 1,108 g of triethanolamine. The mixture is stirred to dissolve the solid material and is then heated and cooled slowly to 20°C. The formed precipitate is filtered off, washed twice with 1000 ml of cold, anhydrous ethanol and dried at 45°C and 0.1 mm Hg. The corresponding tris-hydroxyethylammonium salt is obtained which melts at 115-117°C. The salt is identical to the salt from e.g. 3.

Utgangsstoffet fremstilles som følger: En opp-løsning av 1325 g 1-metylpyrrol-2-karboksylsyre i 2400 ml dimetylformamid settes, under omrøring i en nitrogenatmosfære og avkjøling med is, til en suspensjon som er fremstilt av 568,5 g 50%-ig natriumhydrid i mineralolje og 2400 ml dimetylformamid. Reaksjonsblandingen blandes deretter før: med 1000 ml dimetylformamid og deretter med 4316 g metyljodid under omrøring og ved en temperatur under 88°C. Omr< ingen fortsettes natten over ved værelsestemperatur, deret-avkjøles blandingen til 10°C og blandes med 106 00 ml vann. Blandingen ekstraheres tre ganger med 5300 ml etyleter, ekstraktet vaskes med 5300 ml vandig natriumkarbonatoppløs-ning og 5300 ml vann, tørkes og inndampes. Man får den ol; aktige 1-metylpyrrol-2-karboksylsyremetylester. The starting material is prepared as follows: A solution of 1325 g of 1-methylpyrrole-2-carboxylic acid in 2400 ml of dimethylformamide is added, with stirring in a nitrogen atmosphere and cooling with ice, to a suspension which is prepared from 568.5 g of 50% sodium hydride in mineral oil and 2400 ml of dimethylformamide. The reaction mixture is then mixed first: with 1000 ml of dimethylformamide and then with 4316 g of methyl iodide with stirring and at a temperature below 88°C. Stirring is continued overnight at room temperature, whereupon the mixture is cooled to 10°C and mixed with 10600 ml of water. The mixture is extracted three times with 5300 ml of ethyl ether, the extract is washed with 5300 ml of aqueous sodium carbonate solution and 5300 ml of water, dried and evaporated. You get it etc; active 1-methylpyrrole-2-carboxylic acid methyl ester.

En oppløsning av 16 04 g av sistnevnte forbindeli i 2650 ml acetonitril settes hurtig til en suspensjon som fremstilt av 107 g 50%-ig natriumhydrid i mineralolje og 26 5 0 ml dimetylformamid under omrøring i en nitrogenatmosfære. Blandingen oppvarmes 2 timer ved 81°C og avkjøles deretter til 10°C, blandes til slutt med 25400 ml vann i løpet av 15 min. Blandingen vaskes tre ganger med 9000 ml dietyleter, omrøres 45 min. ved 10 mm Hg for å fjerne diet; eteren og surgjøres med 6400 ml 6-normal klorhydrogensyre. De dannede krystaller adskilles, vaskes 4 ganger med 2400 i vann og 1 gang med 2400 ml isopropanol og tørkes ved 60°C og 5 mm Hg. Man får 1-metyl-3-okso-2-pyrrolpropionitril s< smelter ved 106-018°C. A solution of 1604 g of the latter compound in 2650 ml of acetonitrile is quickly added to a suspension prepared from 107 g of 50% sodium hydride in mineral oil and 2650 ml of dimethylformamide while stirring in a nitrogen atmosphere. The mixture is heated for 2 hours at 81°C and then cooled to 10°C, finally mixed with 25400 ml of water during 15 min. The mixture is washed three times with 9000 ml of diethyl ether, stirred for 45 min. at 10 mm Hg to remove diet; the ether and acidified with 6400 ml of 6-normal hydrochloric acid. The formed crystals are separated, washed 4 times with 2400 ml of water and 1 time with 2400 ml of isopropanol and dried at 60°C and 5 mm Hg. 1-Methyl-3-oxo-2-pyrrolepropionitrile is obtained which melts at 106-018°C.

Eksempel 10 Example 10

1- metyl- p- okso- g-( 2, 6- diklorfenylkarbamoyl)- 2- pyrrolpropionitril 1- methyl- p- oxo- g-(2, 6- dichlorophenylcarbamoyl)- 2- pyrrolepropionitrile

En filtrert oppløsning av 4,4 g 2,6-diklorf enyl-isocyanat i 30 ml toluen blandes med 2,5 g 1-metyl-3-okso-: pyrrolpropionitril og 2,1 g trietylamin under omrøring. Blandingen hensettes natten over ved værelsestemperatur og filtreres deretter. Det faste materiale vaskes med toluen og dietyleter, opptas i 50 ml metanol og oppløsningen helli i en blanding av 6 ml 5-normal klorhydrogensyre og 300 ml vann. De dannede krystaller adskilles, vaskes med vann, tørkes, tritureres med etanol og omkrystalliseres fra metai Man får 1-metyl-3-okso-a-(2,6-diklorfenylkarbamoyl)-2-pyrn propionitril som smelter ved 196-199°C. A filtered solution of 4.4 g of 2,6-dichlorophenyl isocyanate in 30 ml of toluene is mixed with 2.5 g of 1-methyl-3-oxo-pyrrolepropionitrile and 2.1 g of triethylamine with stirring. The mixture is left overnight at room temperature and then filtered. The solid material is washed with toluene and diethyl ether, taken up in 50 ml of methanol and the solution poured into a mixture of 6 ml of 5-normal hydrochloric acid and 300 ml of water. The formed crystals are separated, washed with water, dried, triturated with ethanol and recrystallized from metai 1-methyl-3-oxo-a-(2,6-dichlorophenylcarbamoyl)-2-pyrene propionitrile is obtained which melts at 196-199°C .

Eksempel 11 Example 11

1- metyl- p- okso- g-( p- metoksyfenylkarbamoyl)- 2- pyrrolpropionitril og 1- methyl- p- oxo- g-( p- methoxyphenylcarbamoyl)- 2- pyrrolepropionitrile and

1 - metyl- ft- okso- g- ( p- metyltiof enylkarbamoyl) - 2- pyrrolpropionitril 1 - methyl- ft- oxo-g-( p- methylthio enylcarbamoyl) - 2- pyrrolepropionitrile

En suspensjon av 2 g 1-metyl-p-okso-2-pyrrolpropionitril i 50 ml toluen og 1,6 g trietylamin behandles med 2,1 g p-metoksyfenylisocyanat. Blandingen oppvarmes svakt til opp-løsning av det faste material og hensettes natten over ved værelsestemperatur. Deretter inndampes det, residuet opptas i metanol og blandes med 10 ml 10%-ig vandig natriumhydrok-sydoppløsning og 250 ml vann. Den alkaliske oppløsning filtreres, surgjøres med 5-normal klorhydrogensyre og den dannede utfelling adskilles. Utfellingen vaskes med vann, tørkes, tritureres med varm blanding av metanoleddiksyreetylester og omkrystalliseres fra eddiksyreetylester. Man får 1 -rnetyl-p-okso-g- (p-metoksyf enylkarbamoyl) -2-pyrrolpropionitril som smelter ved 192-193°C. A suspension of 2 g of 1-methyl-p-oxo-2-pyrrolepropionitrile in 50 ml of toluene and 1.6 g of triethylamine is treated with 2.1 g of p-methoxyphenyl isocyanate. The mixture is gently heated to dissolve the solid material and left overnight at room temperature. It is then evaporated, the residue is taken up in methanol and mixed with 10 ml of 10% aqueous sodium hydroxide solution and 250 ml of water. The alkaline solution is filtered, acidified with 5-normal hydrochloric acid and the precipitate formed is separated. The precipitate is washed with water, dried, triturated with a hot mixture of methanolic ethyl acetate and recrystallized from ethyl acetate. One obtains 1-methyl-p-oxo-g-(p-methoxy enylcarbamoyl)-2-pyrrolepropionitrile which melts at 192-193°C.

På analog måte fremstillses også 1-metyl-p-okso-a-(p-metyltiofenylkarbamoyl)-2-pyrrolpropionitril, smeltepunkt 167-168°C. In an analogous manner, 1-methyl-p-oxo-a-(p-methylthiophenylcarbamoyl)-2-pyrrolepropionitrile is also prepared, melting point 167-168°C.

Eksempel 12 Example 12

1- metyl- p- okso- g-( p- nitrofenylkarbamoyl)- 2- pyrrolpropionitril, 1- metyl- p- okso- g-( p- aminofenylkarbamoyl)- 2- pyrrolpropionitril og 1- methyl- p- oxo- g-( p- nitrophenylcarbamoyl)- 2- pyrrole propionitrile, 1- methyl- p- oxo- g-( p- aminophenylcarbamoyl)- 2- pyrrole propionitrile and

1- metyl- p- okso- g-( p- acetylfenylkarbamoyl)- 2- pyrrolpropionitril 1- methyl- p- oxo- g-( p- acetylphenylcarbamoyl)- 2- pyrrolepropionitrile

En oppløsning av 4,9 g 1-metyl-p-okso-2-pyrrolpropionitril i 50 ml toluen, 5 ml dimetylsulfoksyd og 4 g trietylamin behandles med en oppløsning av 5,7 g p-nitro-fenylisocyanat i en minimal mengde toluen under omrøring. Rekasjonsblandingen hensettes natten over, inndampes og residuet opptas i metanol. Oppløsningen filtreres, fortynnes med vann og 6 ml trietylamin, vaskes med eddiksyreetylester og vaskevæsken ekstraheres en gang med 5%-ig vandig natriumhydroksydoppløsning. De forenede vandige oppløsninger surgjøres med 5-normal klorhydrogensyre og den dannede utfelling adskilles. Denne vaskes med vann, tritureres med en blanding av raetanol-etanol og omkrystalliseres fra dimetylformamid. Man får 1 -metyl-3-okso-ot-(p-nitrofenyl-karbamoyl) -2-pyrrolpropionitril som smelter under spaltning ved 245-250°C. A solution of 4.9 g of 1-methyl-p-oxo-2-pyrrolepropionitrile in 50 ml of toluene, 5 ml of dimethyl sulfoxide and 4 g of triethylamine is treated with a solution of 5.7 g of p-nitro-phenyl isocyanate in a minimal amount of toluene under stirring. The reaction mixture is allowed to stand overnight, evaporated and the residue taken up in methanol. The solution is filtered, diluted with water and 6 ml of triethylamine, washed with acetic acid ethyl ester and the washing liquid is extracted once with 5% aqueous sodium hydroxide solution. The combined aqueous solutions are acidified with 5-normal hydrochloric acid and the precipitate formed is separated. This is washed with water, triturated with a mixture of raethanol-ethanol and recrystallized from dimethylformamide. 1-Methyl-3-oxo-o-(p-nitrophenyl-carbamoyl)-2-pyrrolepropionitrile is obtained which melts during cleavage at 245-250°C.

En oppløsning av 2 g av sistnevnte forbindelse i 220 ml etanol og 2 ml trietylamin hydrogeneres over 0,5 g 10%-ig palladiumkull ved 3,5 atmosfærer og værelsestemperatur l 50 min. Den filtrerte oppløsning Innstampea, residuet opptas i vann, blandes med 1 ml trietylamin og oppløsningen vaskes med eddiksyreetylester og dietyleter. Den surgjøres med 5-normal klorhydrogensyre, utfellingen adskilles, vaskes med vann, tørkes og omkrystalliseres fra vandig metanol. Man får 1 -metyl-JJ-acetoksy-a- (p-acetylaminofenylkarbamoyl) -2-pyrrolakrylnitril som smelter ved 193-195°C under spaltning. A solution of 2 g of the latter compound in 220 ml of ethanol and 2 ml of triethylamine is hydrogenated over 0.5 g of 10% palladium charcoal at 3.5 atmospheres and room temperature for 150 min. The filtered solution Innstampea, the residue is taken up in water, mixed with 1 ml of triethylamine and the solution is washed with acetic acid ethyl ester and diethyl ether. It is acidified with 5-normal hydrochloric acid, the precipitate is separated, washed with water, dried and recrystallized from aqueous methanol. One obtains 1-methyl-JJ-acetoxy-α-(p-acetylaminophenylcarbamoyl)-2-pyrrolacrylonitrile which melts at 193-195°C during decomposition.

Man oppløser 0,5 g av sistnevnte forbindelse 1 0.5 g of the latter compound 1 is dissolved

10 ml eddiksyreanhydrid, koker oppløsningen 10 min. under tilbakeløp og inndaraper. Residuet tritureres med dietyleter og omkrystalliseres av metanoleddiksyreetylester. Man får 1-metyl-3-acetoksy-a-(p-acetylaminofenylkarbamoyl)-2-pyrrolakrylnitril som smelter ved 178-179°C. 10 ml acetic anhydride, boil the solution for 10 min. during backflow and inflow. The residue is triturated with diethyl ether and recrystallized from methanolic ethyl acetate. 1-Methyl-3-acetoxy-α-(p-acetylaminophenylcarbamoyl)-2-pyrrolacrylonitrile is obtained which melts at 178-179°C.

Eksempel 13 Example 13

1- etyl- p- okso- o- fenyl) carbamoyl- 2- pyrgolproplonltrll 1- ethyl- p- oxo- o- phenyl) carbamoyl- 2- pyrgolproplonltrll

En blanding av 2,1 g 1-etyl-£-okso-2-pyrrolpropionitril, 25 ml toluen og 1,6 g trietylamin behandles under omrøring med 1,6 g fenylisocyanat. Blandingen hensettes natten over ved værelsestemperatur, inndampes deretter og oppløses i metanol. Oppløsningen helles i 300 ml vann som inneholder 5 ml 5-normal klorhydrogensyre, utfellingen fraskilles og oppløses i 5%-ig vandig natriumhydroksydoppløs-ning. Oppløsningen filtreres , filtratet surgjøres, det faste material adskilles, vaskes med vann, tørkes og omkrystalliseres fra etanol. Man får 1-etyl-3-okso-a-fenylkarbamoyl-2-pyrrolpropionitril som smelter ved 14 4— 145°C. A mixture of 2.1 g of 1-ethyl-£-oxo-2-pyrrolepropionitrile, 25 ml of toluene and 1.6 g of triethylamine is treated with stirring with 1.6 g of phenyl isocyanate. The mixture is left overnight at room temperature, then evaporated and dissolved in methanol. The solution is poured into 300 ml of water containing 5 ml of 5-normal hydrochloric acid, the precipitate is separated and dissolved in a 5% aqueous sodium hydroxide solution. The solution is filtered, the filtrate is acidified, the solid material is separated, washed with water, dried and recrystallized from ethanol. 1-ethyl-3-oxo-α-phenylcarbamoyl-2-pyrrolepropionitrile is obtained which melts at 14 4-145°C.

Utgangsstoffet fremstilles som følger; En suspensjon som fremstilles av 9,1 g 50%-ig natriumhydrid i mineralolje, ved vasking med petroleter og suspendering i 50 ml dimetylformamid, blandes trinnvis under omrøring og avkjøling med is med 20 g pyrrol-2-karboksylsyremetylester i 50 ml dimetylformamid. Etter oppløsning tilsetter man 25 ml etylbromid og oppvarmer reaksjonsblandingen svakt for å starte den eksotermiske reaksjon. Når denne avtar, tilsetter man ytterligere 5 ml etylbromid og lar blandingen stå natten over. Den behandles med vann og ekstraheres med dietyleter. Ekstraktet vaskes med vann, tørkes, filtreres og inndampes. Man får den oljeaktige 1-etylpyrrol-2-kar-boksylsyremetylester. The starting material is prepared as follows; A suspension which is prepared from 9.1 g of 50% sodium hydride in mineral oil, by washing with petroleum ether and suspending in 50 ml of dimethylformamide, is mixed step by step while stirring and cooling with ice with 20 g of pyrrole-2-carboxylic acid methyl ester in 50 ml of dimethylformamide. After dissolution, 25 ml of ethyl bromide are added and the reaction mixture is heated slightly to start the exothermic reaction. When this subsides, a further 5 ml of ethyl bromide is added and the mixture is allowed to stand overnight. It is treated with water and extracted with diethyl ether. The extract is washed with water, dried, filtered and evaporated. The oily 1-ethylpyrrole-2-carboxylic acid methyl ester is obtained.

En oppløsning av 10 g av sistnevnte forbindelse A solution of 10 g of the latter compound

i 25 ml acetonitril og 25 ml dimetylformamid settes til en suspensjon av 5,5 g 50%-ig natriumhydrid (vasket med petroleter) i 15 ml dimetylformamid og blandingen oppvarmes under omrøring 15 min. på dampbad. Man lar den stå natten over, tilsetter vann, filtrerer og surgjør med 5-normal klorhydrogensyre. Utfellingen adskillles, vaskes med vann og omkrystalliseres fra etanol. Man får 1-etyl~3-okso-2-pyrrolpropionitril som smelter ved 77-79°C. in 25 ml of acetonitrile and 25 ml of dimethylformamide are added to a suspension of 5.5 g of 50% sodium hydride (washed with petroleum ether) in 15 ml of dimethylformamide and the mixture is heated with stirring for 15 min. in a steam bath. You let it stand overnight, add water, filter and acidify with 5-normal hydrochloric acid. The precipitate is separated, washed with water and recrystallized from ethanol. 1-ethyl~3-oxo-2-pyrrolepropionitrile is obtained which melts at 77-79°C.

Eksempel 14 Example 14

1- isobutyl- ft- okso- g- fenylkarbamoyl- 2- pyrrolpropionitril 1- isobutyl- ft- oxo- g- phenylcarbamoyl- 2- pyrrole propionitrile

En oppløsning av 2,5 g 1 -isobutyl-|3-okso-2-pyrrolpropionitril i 30 ml toluen og 1,6 g trietylamin blandes med 1,6 g fenylisocyanat under omrøring. Blandingen hensettes natten over, filtreres og residuet oppløses i 5%-ig vandig natriumhydroksydoppløsning. Oppløsningen filtreres, surgjøres med 5-normal klorhydrogensyre og ekstraheres med en blanding av dietyleter-eddiksyreetylester. Den organiske oppløsning vaskes med vann, tørkes og inndampes. Residuet tritureres med etanol og omkrystalliseres fra metanol. Man får 1-isobutyl-p-okso-a-fenylkarbamoyl-2-pyrrolpropionitril som smelter ved 134-135°C. A solution of 2.5 g of 1-isobutyl-|3-oxo-2-pyrrolepropionitrile in 30 ml of toluene and 1.6 g of triethylamine is mixed with 1.6 g of phenyl isocyanate while stirring. The mixture is allowed to stand overnight, filtered and the residue dissolved in 5% aqueous sodium hydroxide solution. The solution is filtered, acidified with 5-normal hydrochloric acid and extracted with a mixture of diethyl ether-ethyl acetate. The organic solution is washed with water, dried and evaporated. The residue is triturated with ethanol and recrystallized from methanol. 1-isobutyl-p-oxo-a-phenylcarbamoyl-2-pyrrolepropionitrile is obtained which melts at 134-135°C.

Utgangsstoffet fremstilles som følger: Man The starting material is prepared as follows: Mon

setter 13 g pyrrol-2-karboksylsyremetylester under omrøring til en suspensjon som er fremstilt av 5,5 g 50%-ig natriumhydrid i mineralolje, ved vasking med petroleter og suspen- adds 13 g of pyrrole-2-carboxylic acid methyl ester with stirring to a suspension prepared from 5.5 g of 50% sodium hydride in mineral oil, by washing with petroleum ether and suspending

dering i 70 ml dimetylformamid. Bladningen blandes deretter i 40 g isobutylbromid og oppvarmes under omrøring 10 min. på dampbad. Reaksjonsblandingen hensettes natten over og behandles deretter med vann og ekstraheres med dietyleter. Ekstraktet vaskes med vann, tørkes og inndampes. Man får den oljeaktige 1-isobutylpyrrol-2-karboksylsyre-metylester. dering in 70 ml of dimethylformamide. The leaf is then mixed in 40 g of isobutyl bromide and heated with stirring for 10 min. in a steam bath. The reaction mixture is allowed to stand overnight and is then treated with water and extracted with diethyl ether. The extract is washed with water, dried and evaporated. The oily 1-isobutylpyrrole-2-carboxylic acid methyl ester is obtained.

En oppløsning av 10 g av sistnevnte forbindelse A solution of 10 g of the latter compound

i 15 ml acetonitril settes under omrøring til en suspensjon som er fremstilt av 5 g 50%-ig natriumhydrid i mineralolje, ved vasking med petroleter og suspendering i 25 ml dimetylformamid. Etter avslutning av den brusende reaksjon oppvarmes blandingen 3 0 min. på dampbad. I løpet av denne tid brukes natriumhydridet opp. Man lar blandingen stå natten over ved værelsestemperatur, blander med vann og surgjør med 5-normal klorhydrogensyre. Blandingen ekstraheres med dietyleter, ekstraktet vaskes med vann, tørkes og inndampes. Man får det oljeaktige 1-isobutyl-Ø-okso-2-pyrrolpropionitril. in 15 ml of acetonitrile is added with stirring to a suspension which is prepared from 5 g of 50% sodium hydride in mineral oil, by washing with petroleum ether and suspending in 25 ml of dimethylformamide. After completion of the effervescent reaction, the mixture is heated for 30 min. in a steam bath. During this time, the sodium hydride is used up. The mixture is allowed to stand overnight at room temperature, mixed with water and acidified with 5-normal hydrochloric acid. The mixture is extracted with diethyl ether, the extract is washed with water, dried and evaporated. The oily 1-isobutyl-Ø-oxo-2-pyrrolepropionitrile is obtained.

Eksempel 15 Example 15

1, 3, 5- trimetyl- 4- etoksykarbonyl- g- okso- g- fenylkarbamoyl- 2-2- pyrrolpropionitril og 1, 3, 5- trimethyl- 4- ethoxycarbonyl- g- oxo- g- phenylcarbamoyl- 2-2- pyrrole propionitrile and

1, 3, 5- trimetyl- 4- etoksykarbonyl- 3- okso- g-( p- fluorfenylkar-bamoyl) - 2- pyrrolpropionitril 1, 3, 5- trimethyl- 4- ethoxycarbonyl- 3- oxo- g-( p- fluorophenylcarbamoyl) - 2- pyrrolepropionitrile

En oppløsning av 1,6 g 1,3,5-trimetyl-4-etoksykarbonyl-3-okso-2-pyrrolpropionitril i 30 ml tørr toluen og 0,8 g vannfri trietylamin blandes under omrøring med 0,8 g fenylisocyanat. Blandingen oppvamres 10 min. på dampbad og hensettes natten over ved værelsestemperatur. Deretter inndampes den, residuet opptas i metanol og opp-løsningen behandles med 2 ml 5-normal klorhydrogensyre og 200 ml vann. De dannede krystaller adskilles og vaskes med vann, tritureres med en blanding av metanol-etanol og omkrystalliseres fra metanol. Man får 1,3,5-trimetyl-4-etoksykarbonyl-3-okso-g<->fenylkarbamoyl-2-pyrrolpropionitril som smelter ved 164-166°C. A solution of 1.6 g of 1,3,5-trimethyl-4-ethoxycarbonyl-3-oxo-2-pyrrolepropionitrile in 30 ml of dry toluene and 0.8 g of anhydrous triethylamine is mixed with stirring with 0.8 g of phenyl isocyanate. The mixture is heated for 10 min. on a steam bath and leave overnight at room temperature. It is then evaporated, the residue is taken up in methanol and the solution is treated with 2 ml of 5-normal hydrochloric acid and 200 ml of water. The formed crystals are separated and washed with water, triturated with a methanol-ethanol mixture and recrystallized from methanol. 1,3,5-trimethyl-4-ethoxycarbonyl-3-oxo-g<->phenylcarbamoyl-2-pyrrolepropionitrile is obtained which melts at 164-166°C.

På analog måte fremstilles også 1,3 , 5-trimetyl-4-etoksykarbonyl-|3-okso-g-(p-fluorfenylkarbamoyl)-2-pyrrolpropionitril, smeltepunkt 178-179°C og 1,3,5-trimetyl-4-etoksykarbonyl-p-okso-a-(p-klorfenylkarbamoyl)-2-pyrrolpropionitril, smeltepunkt 238-241°C under spaltning. 1,3,5-trimethyl-4-ethoxycarbonyl-|3-oxo-g-(p-fluorophenylcarbamoyl)-2-pyrrolepropionitrile, melting point 178-179°C and 1,3,5-trimethyl-4 -ethoxycarbonyl-p-oxo-a-(p-chlorophenylcarbamoyl)-2-pyrrolepropionitrile, melting point 238-241°C with decomposition.

Utgangsstoffet fremstilles som følger: En suspensjon av 3,6 g 50%-ig natriumhydrid i mineralolje (vasket med petroleter) og 50 ml dimetylformamid blandes under omrøring med 16 g 3,5-dimetylpyrrol-2,4-dikarboksylsyre-dietylester i 25 ml dimetylformamid porsjonsvis. Blandingen blandes etter forbruk av natriumhydrid med 4 0 ml metyljodid og hensettes natten over ved værelsestemperatur. Blandingen behandles deretter med vann, det dannede faste materiale adskilles og tørkes i luft for å fjerne overskytende metyljodid. Det faste materiale vaskes med vann, tørkes og omkrystalliseres fra etanol. Man får 1,3,5-trimetylpyrrol-2, 4-dikarboksylsyre-dietylester. The starting material is prepared as follows: A suspension of 3.6 g of 50% sodium hydride in mineral oil (washed with petroleum ether) and 50 ml of dimethylformamide is mixed with stirring with 16 g of 3,5-dimethylpyrrole-2,4-dicarboxylic acid diethyl ester in 25 ml dimethylformamide in portions. After consumption of sodium hydride, the mixture is mixed with 40 ml of methyl iodide and allowed to stand overnight at room temperature. The mixture is then treated with water, the solid formed is separated and dried in air to remove excess methyl iodide. The solid material is washed with water, dried and recrystallized from ethanol. 1,3,5-trimethylpyrrole-2, 4-dicarboxylic acid diethyl ester is obtained.

En oppløsning av 13,9 g av sistnevnte forbindelse i 30 ml acetonitril og 30 ml dimetylformamid settes under omrøring til en suspensjon som er fremstilt av 5,5 g 50%-ig natriumhydrid i mineralolje (vasket med petroleter) og sus-penderes i 60 ml dimetylformamid. Blandingen oppvarmes på dampbad 15 min. og den dannede oppløsning hensettes natten over. Blandingen behandles deretter med vann, den vandige oppløsning filtreres og surgjøres med 5-normal klorhydrogensyre. Utfellingen fraskilles, vaskes med vann, tritureres med etanol og omkrystalliseres fra etanol. Man får 1,3,5-trimetyl-4-etoksykarbonyl-p-okso-2-pyrrolpropionitril som smelter ved 105-107°C. A solution of 13.9 g of the latter compound in 30 ml of acetonitrile and 30 ml of dimethylformamide is added with stirring to a suspension prepared from 5.5 g of 50% sodium hydride in mineral oil (washed with petroleum ether) and suspended in 60 ml of dimethylformamide. The mixture is heated in a steam bath for 15 min. and the formed solution is allowed to stand overnight. The mixture is then treated with water, the aqueous solution is filtered and acidified with 5-normal hydrochloric acid. The precipitate is separated, washed with water, triturated with ethanol and recrystallized from ethanol. 1,3,5-trimethyl-4-ethoxycarbonyl-p-oxo-2-pyrrolepropionitrile is obtained which melts at 105-107°C.

Eksempel 16 Example 16

1- metyl- p- okso- g- fenylkarbamoy1- 2- pyrrolpropionitril 1- methyl- p- oxo- g- phenylcarbamoy1- 2- pyrrolepropionitrile

En oppløsning av 0,3 g 5-(1-metyl-2-pyrrol)-4-fenylkarbamoylisoksazol i 10 ml 5%-ig vandig natrium-hydroksoppløsning og en minimal mengde etanol oppvarmes 5 min. på dampbad. Oppløsningen filtreres deretter og sur-gjøres med 5-normal klorhydrogensyre. De danne krystaller adskilles, vaskes med vann og tritureres med metanol. Man får 1-metyl-3-okso-a-fenylkarbamoyl-2-pyrrolpropionitril som smelter ved 170-172°C. Produktet er identisk med produktet fra eksempel 1,6,8 eller 9. A solution of 0.3 g of 5-(1-methyl-2-pyrrole)-4-phenylcarbamoylisoxazole in 10 ml of 5% aqueous sodium hydroxide solution and a minimal amount of ethanol is heated for 5 min. in a steam bath. The solution is then filtered and acidified with 5-normal hydrochloric acid. The crystals formed are separated, washed with water and triturated with methanol. 1-Methyl-3-oxo-α-phenylcarbamoyl-2-pyrrolepropionitrile is obtained which melts at 170-172°C. The product is identical to the product from example 1, 6, 8 or 9.

Utgangsstoffet fremstilles som følger: En oppløs-ning av 17 g 1-metylpyrrol i 400 ml 1,2-dikloretan blandes først porsjonsvis under omrøring og avkjøling til 10-15°C med 28 g vannfri aluminiumklorid. Deretter tilsetter man 27 g malonsyreetylesterklorid i 50 ml dikloretan i slike porsjoner at temperaturen forblir mellom 10-15°C. Blandingen omrøres i 3i time og deretter lar man temperaturen langsomt øke til 32°C. Reaksjonsblandingen hensettes natten over ved værelsestemperatur, behandles med vann og utrystes. Det organiske sjikt adskilles, vaskes to ganger med vann, tørkes og inndampes. Den som residu dannede mørkebrune olje destil-leres, og fraksjonen som koker ved 105-112°C og 0,25 mm Hg oppfanges. Man får 1-metyl-p-okso-2-pyrrolpropionsyreetyl-ester. The starting material is prepared as follows: A solution of 17 g of 1-methylpyrrole in 400 ml of 1,2-dichloroethane is first mixed in portions while stirring and cooling to 10-15°C with 28 g of anhydrous aluminum chloride. 27 g of malonic acid ethyl ester chloride in 50 ml of dichloroethane are then added in such portions that the temperature remains between 10-15°C. The mixture is stirred for 3 hours and then the temperature is allowed to rise slowly to 32°C. The reaction mixture is left overnight at room temperature, treated with water and shaken. The organic layer is separated, washed twice with water, dried and evaporated. The dark brown oil formed as a residue is distilled, and the fraction boiling at 105-112°C and 0.25 mm Hg is collected. 1-methyl-p-oxo-2-pyrrolepropionic acid ethyl ester is obtained.

En blanding av 3,6 g av sistnevnte forbindelse og 3,9 g N,N<1->difenylformamidin oppvarmes 2\ time ved 145-165°C. Den dannede sprø glassaktige masse pulveriseres, tritureres med dietylester og omkrystalliseres fra etanoleddiksyreetyl-ester. Man får 1-metyl-3-okso-a-anilinometylen-2-pyrrol-propionsyreanilid som smelter ved 178-180°C. A mixture of 3.6 g of the latter compound and 3.9 g of N,N<1->diphenylformamidine is heated for 2 hours at 145-165°C. The brittle glassy mass formed is pulverized, triturated with diethyl ester and recrystallized from ethanol-acetic acid ethyl ester. 1-Methyl-3-oxo-α-anilinomethylene-2-pyrrole-propionic acid anilide is obtained which melts at 178-180°C.

En blanding av 1,4 g av sistnevnte forbindelse, 1,1 g hydroksylaminhydroklorid, 1,2 g pyridin og 150 ml etanol kokes 7 timer under tilbakeløp. Reaksjonsblandingen hensettes natten over, filtreres, inndampes og residuet behandles med vann. Den orangefargede olje blir krystallinsk under henstand. Utfellingen adskilles, vaskes med vann, omkrystalliseres fra etanol. Man får 5-(1-metyl-2-pyrrolyl)-4-fenylkarbamoylisoksazol som smelter ved 100-103°C. Eksempel 17 A mixture of 1.4 g of the latter compound, 1.1 g of hydroxylamine hydrochloride, 1.2 g of pyridine and 150 ml of ethanol is refluxed for 7 hours. The reaction mixture is left overnight, filtered, evaporated and the residue is treated with water. The orange colored oil becomes crystalline on standing. The precipitate is separated, washed with water, recrystallized from ethanol. 5-(1-methyl-2-pyrrolyl)-4-phenylcarbamoylisoxazole is obtained which melts at 100-103°C. Example 17

1, 3, 5- trimetyl- 3- okso- g- fenylkarbamoyl- 2- pyrrolpropionitril og 1, 3, 5- trimethyl- 3- oxo- g- phenylcarbamoyl- 2- pyrrole propionitrile and

1, 3, 5- trimetyl- 3- okso- g-( p- fluorfenylkarbamoyl)- 2- pyrrolpropionitril 1, 3, 5- trimethyl- 3- oxo- g-( p- fluorophenylcarbamoyl)- 2- pyrrolepropionitrile

En suspensjon av 1 g 1 ,3,5-trimetyl-|}-okso-2-pyrrolpropionitril i 30 ml tørr toluen og 0,7 g vannfri trietylamin blandes under omrøring med 0,7 5 g fenylisocyanat. Blandingen oppvarmes 5 min. på dampbad og hensettes natten over ved værelsestemperatur. Det filtreres, residuet opptas i metanol og oppløsningen surgjøres med 1-normal klorhydrogensyre. Den dannede utfelling adskilles, oppløses i 1-normal vandig natriumhydroksydoppløsning, utfelles igjen med 5-normal klorhydrogensyre og vaskes med vann. Man får 1,3,5-trimetyl-3-okso-a-fenylkarbamoyl-2-pyrrolpropionitril som smelter ved 172-174°C. A suspension of 1 g of 1,3,5-trimethyl-|}-oxo-2-pyrrolepropionitrile in 30 ml of dry toluene and 0.7 g of anhydrous triethylamine is mixed with stirring with 0.75 g of phenyl isocyanate. The mixture is heated for 5 min. on a steam bath and leave overnight at room temperature. It is filtered, the residue is taken up in methanol and the solution is acidified with 1-normal hydrochloric acid. The formed precipitate is separated, dissolved in 1-normal aqueous sodium hydroxide solution, precipitated again with 5-normal hydrochloric acid and washed with water. 1,3,5-trimethyl-3-oxo-a-phenylcarbamoyl-2-pyrrolepropionitrile is obtained which melts at 172-174°C.

Utgangsstoffet fremstilles som følger: En blanding av 11,9 g 1,3,5-trimetylpyrrol-2,4-dikarboksylsyre-dietylester og 5 0 ml konsentrert svovelsyre oppvarmes 1 time på dampbad. Den dannede oppløsning helles på is, utfellingen adskilles og vaskes med vann. Deretter opptas den i vandig natriumkarbonatoppløsning, oppløsningen filtreres og filtratet surgjøres med 5-normal klorhydrogensyre. Den dannede utfelling adskilles, vaskes med vann, tørkes og omkrystalliseres fra etanol. Man får 1,3,5-trimetyl-2-karbetoksypyrrol-4-karboksylsyre som smelter under spaltning ved 197-198°C. The starting material is prepared as follows: A mixture of 11.9 g of 1,3,5-trimethylpyrrole-2,4-dicarboxylic acid diethyl ester and 50 ml of concentrated sulfuric acid is heated for 1 hour on a steam bath. The resulting solution is poured onto ice, the precipitate is separated and washed with water. It is then taken up in aqueous sodium carbonate solution, the solution is filtered and the filtrate is acidified with 5-normal hydrochloric acid. The precipitate formed is separated, washed with water, dried and recrystallized from ethanol. 1,3,5-trimethyl-2-carbethoxypyrrole-4-carboxylic acid is obtained which melts during cleavage at 197-198°C.

Man oppvarmer 15 min. under tilbakeløp ved 235-240°C 7,5 g av sistnevnte forbindelse og avkjøler deretter. Residuet opptas i petroleter, oppløsningen filtreres og inndampes. Man får 1,3,5-trimetylpyrrol-2-karboksylsyreetyl-ester som smelter ved 38-40°C. (Produktet er omtalt i US-PS nr. 2.479.972 med et kokepunkt på 102-108°C/3-4 mm Hg). One warms up for 15 min. under reflux at 235-240°C 7.5 g of the latter compound and then cools. The residue is taken up in petroleum ether, the solution is filtered and evaporated. 1,3,5-trimethylpyrrole-2-carboxylic acid ethyl ester is obtained which melts at 38-40°C. (The product is described in US-PS No. 2,479,972 with a boiling point of 102-108°C/3-4 mm Hg).

En oppløsning av 4 g av sistnevnte forbindelse A solution of 4 g of the latter compound

i 10 ml acetonitril settes under omrøring til en suspensjon som er fremstilt av 2 g 50%-ig natriumhydrid i mineralolje (vasket med petroleter) og suspendering i 15 ml dimetylformamid. Blandingen oppvarmes 25 min. på dampbad og hensettes 3 timer ved værelsestemperatur. Blandingen blandes med vann, den vandige oppløsning ekstraheres med dietyleter og sur-gjøres med 5-normal klorhydrogensyre. Krystallene adskilles, vaskes med vann, tørkes og omkrystalliseres fra etanol under tilsetting av aktivt kull. Man får 1 , 3 , 5-trimetyl-(}-okso-2- in 10 ml of acetonitrile is added with stirring to a suspension which is prepared from 2 g of 50% sodium hydride in mineral oil (washed with petroleum ether) and suspension in 15 ml of dimethylformamide. The mixture is heated for 25 min. on a steam bath and leave for 3 hours at room temperature. The mixture is mixed with water, the aqueous solution is extracted with diethyl ether and acidified with 5-normal hydrochloric acid. The crystals are separated, washed with water, dried and recrystallized from ethanol while adding activated charcoal. One obtains 1 , 3 , 5-trimethyl-(}-oxo-2-

pyrrolpropionitril som smelter ved 106-107°C. pyrrolepropionitrile which melts at 106-107°C.

Analogt fåes også 1,3,5-trimetyl-3-okso-a-(p-fluorfenylkarbamoyl)-2-pyrrolpropionitril som etter omkrystal-lisering fra etanol-metanol (1:1) smelter ved 184-186°C. Eksempel 18 Analogously, 1,3,5-trimethyl-3-oxo-a-(p-fluorophenylcarbamoyl)-2-pyrrolepropionitrile is also obtained which, after recrystallization from ethanol-methanol (1:1), melts at 184-186°C. Example 18

1, 2, 5- trimetyl- p- okso- g- fenylkarbamoyl- 3- pyrrolpropionitril og 1, 2, 5- trimethyl- p- oxo- g- phenylcarbamoyl- 3- pyrrole propionitrile and

1, 2, 5- trimetyl-&- okso- g-( p- fluorfenylkarbamoyl)- 3- pyrrolpropionitril 1, 2, 5- trimethyl-&- oxo- g-( p- fluorophenylcarbamoyl)- 3- pyrrole propionitrile

En suspensjon av 1 g 1,2,5-trimetyl-3-okso-3-pyrrolpropionitril i 40 ml toluen og 0,7 g trietylamin behandles med 0,75 g fenylisocyanat og oppvarmes 5 min. på dampbad inntil oppløsning av det faste materiale. Blandingen hensettes natten over, den dannede utfelling adskilles, opptas i metanol og oppløsningen settes til en blanding av 3 ml 5-normal klorhydrogensyre og 250 ml vann. Råproduktet adskilles, vaskes med vann, oppløses i 5%-ig vandig natrium-hydroksydoppløsning, filtreres og det alkaliske filtrat sur-gjøres med 5-normal klorhydrogensyre. Utfellingen adskilles, vaskes med vann, tørkes i luft og omkrystalliseres fra etanol. Man får 1 , 2, 5-trimetyl-3-okso-a-f enylkarbamoyl-3-pyrrolpropionitril som smelter ved 158-160°C. A suspension of 1 g of 1,2,5-trimethyl-3-oxo-3-pyrrolepropionitrile in 40 ml of toluene and 0.7 g of triethylamine is treated with 0.75 g of phenyl isocyanate and heated for 5 min. on a steam bath until the solid material dissolves. The mixture is allowed to stand overnight, the precipitate formed is separated, taken up in methanol and the solution is added to a mixture of 3 ml of 5-normal hydrochloric acid and 250 ml of water. The crude product is separated, washed with water, dissolved in a 5% aqueous sodium hydroxide solution, filtered and the alkaline filtrate acidified with 5-normal hydrochloric acid. The precipitate is separated, washed with water, dried in air and recrystallized from ethanol. 1,2,5-trimethyl-3-oxo-α-phenylcarbamoyl-3-pyrrolepropionitrile is obtained which melts at 158-160°C.

Analogt fåes også det rå 1,2,5-trimetyl-3-okso-a-(p-fluorfenylkarbamoyl)-3-pyrrolpropionitril. Det oppløses i vandig natriumhydrogenkarbonatoppløsning og utfelles med 5-normal klorhydrogensyre og omkrystalliseres fra etanol, Analogously, the crude 1,2,5-trimethyl-3-oxo-α-(p-fluorophenylcarbamoyl)-3-pyrrolepropionitrile is also obtained. It is dissolved in aqueous sodium bicarbonate solution and precipitated with 5-normal hydrochloric acid and recrystallized from ethanol,

med smeltepunkt 171-172°C. with melting point 171-172°C.

Utgangsstoffet fremstilles som følger: En opp-løsning av 7,6 g 1,2,5-trimetylpyrrol-3-karboksylsyreetyl-ester (Ber. 56, 2374 (1923), smeltepunkt etter omkrystall-isering fra metanol 65-66°C) i 20 ml acetonitril settes til en suspensjon av 4 g 50%-ig natriumhydrid i mineralolje og 11 ml dimetylformamid. Blandingen oppvarmes under omrøring The starting material is prepared as follows: A solution of 7.6 g of 1,2,5-trimethylpyrrole-3-carboxylic acid ethyl ester (Ber. 56, 2374 (1923), melting point after recrystallization from methanol 65-66°C) in 20 ml of acetonitrile is added to a suspension of 4 g of 50% sodium hydride in mineral oil and 11 ml of dimethylformamide. The mixture is heated while stirring

20 min. på dampbad og den dannede suspensjon avkjøles i løpet av 90 min. til værelsestemperatur. Suspensjonen helles i 200 ml isvann, den alkaliske vandige oppløsning filtreres og filtratet surgjøres under avkjøling med is med 18%-ig klorhydrogensyre. Utfelling adskilles, vaskes med vann, og tørkes i luft, tritureres i etylester og omkrystalliseres fra metanol. Man får 1,2,5-trimetyl-3-okso-3-pyrrolpropionitril som smelter ved 14 0-141°C. 20 min. on a steam bath and the formed suspension is cooled within 90 min. to room temperature. The suspension is poured into 200 ml of ice water, the alkaline aqueous solution is filtered and the filtrate is acidified while cooling with ice with 18% hydrochloric acid. The precipitate is separated, washed with water, and dried in air, triturated in ethyl ester and recrystallized from methanol. 1,2,5-trimethyl-3-oxo-3-pyrrolepropionitrile is obtained which melts at 140-141°C.

Eksempel 19 Example 19

Idet man går ut fra ekvivalente mengder tilsvarende utgangsstoffer fremstilles også i henhold til fremgangsmåter i de foregående eksempler, spesielt ifølge 1, 4 og 9 følgende forbindelser med formel II, hvori R2 = R3 = H: Starting from equivalent amounts of corresponding starting materials, the following compounds of formula II, in which R2 = R3 = H, are also prepared according to methods in the previous examples, especially according to 1, 4 and 9:

Claims (1)

Analogifremgangsmåte til fremstilling avAnalogy method for the production of terapeutisk aktive substituerte &-okso-a-fenylkarbamoyl-therapeutically active substituted &-oxo-a-phenylcarbamoyl- pyrrolpropionitriler og deres enolderivater med den generellepyrrolepropionitriles and their enol derivatives with the general formel (I):formula (I): hvori Pl betyr en 2- eller 3-pyrrolylrest, som i 1-stillingwherein P1 means a 2- or 3-pyrrolyl residue, as in the 1-position er substituert med C^-C^-alkyl og er substituert i de øvrig-is substituted with C₁-C₁-alkyl and is substituted in the other blivende tre stillinger eller substituert med en til treremaining three positions or substituted by one to three C^-C2~alkylgrupper og/eller en C^-C2~alkoksykarbonyljog PhC^-C2~ alkyl groups and/or a C^-C2~ alkoxycarbonyl group Ph står for fenyl som er usubstituert eller substituert med enstands for phenyl which is unsubstituted or substituted with one til to like eller forskjellige substituenter fra gruppento two identical or different substituents from the group C^-C2~alkyl, C^-C2~alkoksy, C^-C2-alkyltio, hydroksy, haloC₁-C₂alkyl, C₁-C₂alkyl, C₁-C₂alkylthio, hydroxy, halo gen, trifluormetyl, nitro, amino og acetyl-amino; A er engen, trifluoromethyl, nitro, amino and acetyl-amino; Credit oksogruppe eller er en -C^-C2-alkoksy- eller -O-CO-C^-C^-oxo group or is a -C^-C2-Alkoxy- or -O-CO-C^-C^- alkylgruppe, idet det da mellom de to naboplasserte karbonalkyl group, since then between the two neighboring carbons atomer består en dobbeltbinding, eller deres salter medatoms form a double bond, or their salts with baser eller terapeutisk godtagbare salter med baser,bases or therapeutically acceptable salts with bases, karakterisert ved at a) forbindelser med formlene:characterized in that a) compounds with the formulas: hvori Pl og Ph har ovennevnte betydning, adderes, eller b) forbindelse med formlene:in which Pl and Ph have the above meaning, are added, or b) connection with the formulas: hvori X betyr laverealkoksy, laverealkanoyloksy ellerwherein X means lower alkoxy, lower alkanoyloxy or halogen, Pl og Ph har ovennevnte betydning, kondensereshalogen, Pl and Ph have the above meanings, are condensed eller c) forbindelser med formlene:or c) compounds of the formulas: hvori Y betyr laverealkoksykarbonyl, halogenkarbonyl eller cyan, P1 og Ph har ovennevnte betydning, kondenseres, og de dannede iminer hydrolyseres, eller d) en forbindelse med formel:in which Y means lower alkoxycarbonyl, halocarbonyl or cyan, P1 and Ph have the above meaning, is condensed, and the formed imines are hydrolysed, or d) a compound of formula: hvori P1 og Ph har ovennevnte betydning, isomeriseres med en sterk base, ogwherein P1 and Ph have the above meaning, isomerize with a strong base, and om ønsket, overføres en fremstilt forbindelse med formel (I), hvori A betyr en okso-gruppe ved behandling med en diazo-alkan til en forbindelse av formel (I) hvori A står for C^-C2_alkoksy, eller ved behandling med et alkansyreanhydrid til en forbindelse av formel (I) hvori A betyr -0-CO-C.j-C^-alkyl, og/eller om ønsket, overføres en fremstilt forbindelse av formel (I) hvori A betyr en okso-gruppe, til et salt med en base, eller et fremstilt enolsalt overføres til det frie enol eller til et annet salt med en base.if desired, a prepared compound of formula (I), in which A means an oxo group, is transferred by treatment with a diazo-alkane to a compound of formula (I) in which A stands for C₁-C₂₂₂ alkoxy, or by treatment with an alkanoic anhydride to a compound of formula (I) in which A means -O-CO-C.j-C^-alkyl, and/or if desired, a prepared compound of formula (I) in which A means an oxo group is transferred to a salt with a base, or a produced enol salt is transferred to the free enol or to another salt with a base.
NO801733A 1979-06-11 1980-06-10 ANALOGUE PROCEDURES FOR THE PREPARATION OF THERAPEUTIC ACTIVE ALPHACARBAMOYL-PYRROLPROPIONITRILS. NO155197C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4606379A 1979-06-11 1979-06-11

Publications (3)

Publication Number Publication Date
NO801733L NO801733L (en) 1980-12-12
NO155197B true NO155197B (en) 1986-11-17
NO155197C NO155197C (en) 1987-02-25

Family

ID=21941390

Family Applications (1)

Application Number Title Priority Date Filing Date
NO801733A NO155197C (en) 1979-06-11 1980-06-10 ANALOGUE PROCEDURES FOR THE PREPARATION OF THERAPEUTIC ACTIVE ALPHACARBAMOYL-PYRROLPROPIONITRILS.

Country Status (22)

Country Link
EP (2) EP0021207B1 (en)
JP (1) JPS562961A (en)
KR (4) KR840001131B1 (en)
AT (1) ATE14724T1 (en)
AU (1) AU539967B2 (en)
CA (1) CA1133917A (en)
CY (1) CY1426A (en)
DD (1) DD151307A5 (en)
DE (1) DE3070951D1 (en)
DK (1) DK155996C (en)
ES (1) ES8104223A1 (en)
FI (1) FI71129C (en)
GR (1) GR69239B (en)
HK (1) HK50288A (en)
HU (1) HU182670B (en)
IE (1) IE50288B1 (en)
IL (1) IL60269A (en)
KE (1) KE3795A (en)
NO (1) NO155197C (en)
NZ (1) NZ193995A (en)
PT (1) PT71367A (en)
ZA (1) ZA803461B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2127809B (en) * 1982-09-28 1986-03-12 Ciba Geigy Ag Certain b-oxo-a-carbamoyl-pyrrolepropionitriles
DE3247454A1 (en) * 1982-12-22 1984-06-28 Laboratorios Bago S.A., Buenos Aires Substituted 3-phenyl-5-methylisoxazole-4-carboxanilides, process for their preparation and pharmaceutical compositions containing these compounds
DE3525623A1 (en) * 1985-07-18 1987-01-22 Celamerck Gmbh & Co Kg Fungicidally effective acrylic acid amides
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
GB8619433D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
JPH02502534A (en) * 1987-12-18 1990-08-16 チバ‐ガイギー アクチェンゲゼルシャフト Tromethamine salt of 1-methyl-β-oxo-α-(phenylcarbamoyl)-2-pyrrolepropionitrile
IL92508A0 (en) * 1988-12-08 1990-08-31 Ciba Geigy Ag Novel alpha-cyano-beta-oxopropionamides
GR880100839A (en) * 1988-12-15 1994-03-31 Ciba Geigy Tromethamine salt of 1-methyl-b-oxo-a-(phenylcarbamoyl)-2-pyrrolepropionitrile
AU625688B2 (en) * 1989-01-31 1992-07-16 Merrell Dow Pharmaceuticals Inc. Method of using aryl- or heteroaryl-1-alkyl-pyrrole-2- carboxylic acid compounds in the treatment of interleukin-1 mediated conditions
GB9720899D0 (en) * 1997-10-01 1997-12-03 Pharmacia & Upjohn Spa Condensed heterocyclic compounds
JP2005520835A (en) * 2002-03-19 2005-07-14 バイエル ケミカルズ アクチエンゲゼルシャフト Squarylium dye as a light-absorbing compound in the information layer of optical data carriers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE861500C (en) * 1942-07-05 1953-01-05 Beth Ag Maschf Purge air filter
GB1201061A (en) * 1966-08-26 1970-08-05 Endo Lab Oxo pyrroles and process for preparing same
NL186239B (en) * 1975-06-05 Hoechst Ag PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT WITH ANTIFLOGISTICAL AND / OR ANALGETICAL ACTION AND PROCEDURE FOR THE PREPARATION OF A 2-HYDROXYETHYLIDE ENCYANAACETIC ANILIDE SUITABLE FOR USE IN THIS PROCESS.
NL178596C (en) * 1975-06-05 1986-04-16 Hoechst Ag METHOD FOR PREPARING A MEDICINAL PRODUCT WITH ANTIFLOGISTIC AND / OR ANALGETIC ACTION, AND A METHOD FOR PREPARING THEIR PRODUCT TO BE USED AS MEDICINAL COMPOUNDS 5-METHYLISOXAZOLE-4-CARBONIC ACID.
DE2654797A1 (en) * 1976-12-03 1978-06-08 Hoechst Ag PROCESS FOR THE PREPARATION OF ISOXAZOLE DERIVATIVES

Also Published As

Publication number Publication date
ES492278A0 (en) 1981-04-01
HK50288A (en) 1988-07-15
IL60269A (en) 1983-12-30
ES8104223A1 (en) 1981-04-01
ATE14724T1 (en) 1985-08-15
KR840001133B1 (en) 1984-08-09
DK155996B (en) 1989-06-12
KE3795A (en) 1988-03-11
EP0021207B1 (en) 1985-08-07
AU5917380A (en) 1980-12-18
GR69239B (en) 1982-05-11
FI801840A (en) 1980-12-12
NO801733L (en) 1980-12-12
NZ193995A (en) 1983-03-15
JPH0351704B2 (en) 1991-08-07
PT71367A (en) 1980-07-01
DD151307A5 (en) 1981-10-14
KR840004678A (en) 1984-10-22
DE3070951D1 (en) 1985-09-12
NO155197C (en) 1987-02-25
JPS562961A (en) 1981-01-13
DK250180A (en) 1980-12-12
EP0021207A1 (en) 1981-01-07
KR840001134B1 (en) 1984-08-09
FI71129C (en) 1986-11-24
HU182670B (en) 1984-02-28
EP0143142A2 (en) 1985-06-05
KR840001131B1 (en) 1984-08-09
DK155996C (en) 1989-11-06
AU539967B2 (en) 1984-10-25
CY1426A (en) 1988-09-02
KR830002708A (en) 1983-05-30
IL60269A0 (en) 1980-09-16
IE50288B1 (en) 1986-03-19
EP0143142A3 (en) 1985-07-17
CA1133917A (en) 1982-10-19
ZA803461B (en) 1981-06-24
KR840004677A (en) 1984-10-22
IE801185L (en) 1980-12-11
KR840001132B1 (en) 1984-08-09
FI71129B (en) 1986-08-14

Similar Documents

Publication Publication Date Title
US4705882A (en) N-naphthoylglycine derivatives
US3635982A (en) Amino-substituted-quinoxalinyloxazolidines and -oxazines
US3275644A (en) Certain 1-azolylindol-3-ylaliphatic acids
US3810906A (en) N1-heteroacylated phenylhydrazines
US4892963A (en) N-phenyl amide compounds
NO155197B (en) ANALOGUE PROCEDURES FOR THE PREPARATION OF THERAPEUTIC ACTIVE ALPHACARBAMOYL-PYRROLPROPIONITRILS.
PL165653B1 (en) Method of obtaining novel derivatives of azaoxyindole
US4076709A (en) Thienothiazines
EP0181136B1 (en) Oxindole antiinflammatory agents
US4755509A (en) Heterocyclic aldose reductase inhibitors and methods of using them
CA2032231C (en) Substituted oxophthalazinyl acetic acids and analogs thereof
DK149230B (en) METHOD OF ANALOGUE FOR THE PREPARATION OF 5-BENZOYL-6-HYDROXY-INDANE-1-CARBOXYLIC ACID DERIVATIVES OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF
NO180300B (en) Hydroxyamidine derivatives, pharmaceutical compositions containing them and their use in the preparation of pharmaceutical compositions
CA2016504C (en) Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
DK160760B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF N-NAPHTHOYLGYLININE DERIVATIVES
NO764039L (en)
US4090020A (en) Thienothiazine derivatives
US5258396A (en) Thiazole derivatives
US4175085A (en) Thienothiazine derivatives
US3564008A (en) Process for preparing 1-acyl-2-phenyl-3-indolylaliphatic acid derivatives
CH498856A (en) Pharmaceutical furazan derivatives prodn
PL145950B1 (en) Method of obtaining 1,3-diacyl-2-ketoindoles
US4307092A (en) 1-Oxo-5H-pyrimido[2,1-C]benzoxazine-2-carboxylic acid esters
US4134898A (en) N-Carbalkoxymethylsulfamoyl thiophene carboxylic acid alkyl esters
US3300496A (en) Derivatives of pyrimidine-5-carboxylic acid